

CURRICULUM VITAE

NAME: Ann Richmond, Ph.D.

ADDRESS: Department of Pharmacology
432 PRB
Vanderbilt University School of Medicine
23rd Ave S @ Pierce
Nashville, TN 37232

TELEPHONE: 615-343-7777 (work)
615-377-7760 (home)

EDUCATION: University of Louisiana Monroe
Monroe, Louisiana
B.S., 1963 - 1966

Louisiana State University
Baton Rouge, Louisiana
M.N.S. (Zoology), 1970 - 1972

Emory University
Atlanta, Georgia
Ph.D. (Developmental Biology), 1976 - 1979



RESEARCH

T: Inflammation and cancer; the role of chemokines in normal physiology and cancer; signal transduction mechanisms for chemokines; novel therapeutics for treatment of melanoma and breast cancer; combining targeted therapies with immune checkpoint inhibitors to enhance survival

PROFESSIONAL EXPERIENCE:

Professor of Pharmacology and Dermatology, 2018-present
Professor and Vice Chair of Cancer Biology, Vanderbilt University, 2000-2018
Ingram Professor of Cancer Research, VUMC, 2005-present
Assistant Dean of Biomedical Research, Education and Training, VUMC, 2005 - 2010
Professor of Cell Biology, Vanderbilt University, 1995-2005
Professor of Medicine, Vanderbilt University, 1997-2018
Professor of Dermatology, Vanderbilt University School of Medicine, 2018-present
Associate Professor of Cell and Developmental Biology, Vanderbilt Univ, 1989 - 1995
Senior Research Career Scientist, Department of Veterans Affairs, 1999-2027
Associate Career Scientist, Department of Veterans Affairs 1989 - 1999
Associate Professor of Medicine, Emory University, 1988 - 1989
Assistant Professor of Medicine, Emory University, 1982 - 1987
Assistant Professor of Anatomy, Emory University, 1985 - 1989
Instructor in Medicine, Emory University, 1980 – 1982
Postdoctoral trainee in the Department of Medicine, Emory University School of Medicine, Emory University, 1979 – 1982
Teaching Assistant, Emory University, 1978 - 1979(Comparative Vertebrate Embryology Metabolic Biology)
Classroom Teacher, 1966 - 1972, 1974. (Chemistry, Physics, and Biology)

CHAIRPERSON / DIRECTOR:

Director of the Tumor Biology Section, Winship Cancer Center, Emory University, 1985-1989
Chair, Interdepartmental Endocrine Group, Emory University, 1986-1987
Chair, VAMC-R&D Budget Committee, 1988-1989
Sigma XI, President, 1988-1989; Vice President, 1987-1988
Director of Graduate Studies, Department of Cell Biology, Vanderbilt University, 1993-1995
Organizer/Chair of the 1st Gordon Research Conference on Chemotactic Cytokines, 1994
Chair, Cell and Developmental Biology Curriculum Review Committee, 1993-94
Chair, Cell and Developmental Biology Secondary Appointments Review Committee, 1999
Organizer, International Cytokine Society Meeting, Hilton Head, S.C., 1999
Organizer for the Keystone Signal Transduction Symposia, 2001
Chair, Vice Chancellor's Committee for the Faculty Incentive/Reward Program, 1999-2006
Vice Chair, Department of Cancer Biology, 2000-2018
Organizer for the Keystone Chemokines and Chemokine Receptors Symposia, 2003
Director of Graduate Studies for the Master Laboratory Science Program, VUMC, 2004-2006
Associate Director of Education, Vanderbilt Ingram Cancer Center, 2004-2020
Assistant Dean of Biomedical Research, Education and Training, 2005-2010
Co-PI, U54 Partnership between VICC, Meharry and TSU 2012-2021
University of Kentucky Cancer Biology Training Center, EAB Chair 2014-present
Markey Cancer Center External Advisory Board, University of Kentucky 2014-present
Director of the Program in Cancer Biology, 2018-present
Search Committee for Program Leader for the Vanderbilt Ingram Cancer Center, 2023-2024

**REFEREE
ASSIGNMENTS:**

National Merit Review Board for Oncology, Veterans Administration, 1986-1988
CBY-2 Study Section, NIH 1989, Ad Hoc Reviewer
ACS Biochemical Endocrinology Study Section, July, 1990 and February, 1995
Department of Veterans Affairs, 1994-1995, Ad Hoc Reviewer
NIH Study Section, CBY-2, Full Member, 1991-1994
NIH Program Project Site Visit Reviewer-1994, 1995
NCI Intramural Program Review: Laboratory Molecular Immuno regulation, 2000-04; 2010
NIH Reviewers Reserve-1995-present
Merit Review Board for Oncology, Department of Veterans Affairs, 2000-2004, 2006, 2012
Editorial Board for the *Journal of Leukocyte Biology* 1995-present
Editorial Board, *Journal of Biological Chemistry*, 1997-2001
Editorial Board, *Pigment Cell and Melanoma Research*, 2010-present.
Editorial Board, *Frontiers in Oncology—Assoc Editor, 2021-present*
Editorial Board, *Cancers—2021-present*
NIH Reviewer for Special Thematic Review, December, 2004
NCI SPORE Review Panel, March, 2007, Oct 2007, Sept 2009; Spring 2011; 2012
NIH Reviewer for CAMP, February 2007 and 2008, Fall 2009; Spring 2011, Spring 2012
VA Advisory Board for Research Career Scientist positions, VA Central Office, 2008 –13
Lloyd Foundation for Melanoma Research, Scientific Advisory Board, 2012-2022
Chair of the 2013-2014 Landon Foundation AACR INNOVATOR Award for TME
NIH Study Section, CAMP Full Member, 2015-2019
NIH Ad Hoc Study Section Member, February 2014, February 2015.Fall 2020
Gertrude B. Elion Cancer Research AACR Scientific Review Committee
NCI PO1 Project Review—2018
ORD Special Emphasis Panel ZRD1RCSA-P 2018-2019
NCCN Review Panel, 2019-present
AACR Immuno-Oncology Research Fellowship Award and AACR Bristol Myers Squibb
Midcareer Female Investigator Award Review 2019-2021
NIH Fellowship Review Board, 2020
Cancer Biology ZRG—Ad hoc, 2021

Reviewer for the Pathobiology Program, Brown University, 2021
NCI Site Visit Team for Moffitt CCSG renewal 2021
NCI Tumor Biology Special Study Section Co-Chair, April, 2022
NCI DT Study Section Ad Hoc reviewer, June 2022
VA DEI Study Section, September 2022
NIH Intramural Program Advisory Board, June 2023
Review Panel for Barnwell Awards, April 2023
Review Panel for Middleton Award, 2024
VA OncE Study Section, May, 2024

**JOURNAL
REVIEWER FOR:**

Cancer Research; Clin Cancer Res; Journal of Immunology, Journal of Clinical Investigations; Nature; Nature Immunology Reviews, Nature Reports, J Cell Biol; J. Leukocyte Biology; Journal of Biological Chemistry, Biochemistry; FASEB; Blood; J Cell Science; Exp Cell Res; Clin Cancer Res; PNAS;; Science Signal Transduction; Breast Cancer Research; Oncogene, Cancer Discovery, Science, Cancer Immunology Research, Cancers, Frontiers in Immunology; Scientific Reports; Cell Reports.

HONORS AND AWARDS:

Legacy Award, Society for Leukocyte Biology, 2019
Delores Shockley Partnership Award 2018
AAAS Fellow, 2018
William S. Middleton Award, Excellence in Biomedical Laboratory Research, 2016
Ingram Endowed Professorship, 2005-present
Charles Park Award for Research Revealing Insights into Physiology and Pathology, 2014
President, Society of Leukocyte Biology, 2014-2016
Vanderbilt Ingram Cancer Center Impact Award in Basic Research, 2010, 2016
Nominee for Outstanding Postdoc Mentor Award, 2009
Delegate to the ELAM program for Executive Leadership in Academic Medicine, 2002
Delegate to the AAMC Leadership Conference for Senior Women, 1999
Sigma XI, 1978 to present; President, 1988
Research Career Scientist, DVA 1988 – 1999
Senior Career Scientist Award, DVA 1999-2027
Veterans Affairs Merit Award, 1983 – 2025
NCI New Investigator Award, 1983 – 1986
NIH Individual NRSA, 1981 – 1983
Cokesbury Award, 1977, 1978
NSF Fellow, 1970 – 1972

**ORGANIZATIONS
AND SOCIETIES:**

American Society for Cell Biology 1984 - 2019
American Association for Cancer Research 1984-present, Program Committee, 1992
Women in Cancer Research, 2008-present; Membership Development Committee, 2012-
Society for Melanoma Research, 2003-present
Society for Leukocyte Biology--Nominations Committee, 1998, Council Member, 99-02,
SLB President Elect, 2012-2014; President 2014-2016; Nominations Committee, 2020-2022.
International Cytokine Society-- Treasurer, 1995-97, Secretary 2001-2004, Nominations
Committee, 1998-Society Member since 1994
American Academy for the Advancement of Science –member
Society for Immunotherapy in Cancer, member

PRESENT RESEARCH

PROJECTS:

CURRENT FUNDING:

IK6BX005225 VA Senior Career Scientist Award (Richmond) 2020-2027 VA

This Award is for salary and fringe for Ann Richmond

Project Period Funds: \$1,514,738 over 7 years Current Year \$206,639.

VA Merit Award 101BX002301 (Richmond, PI), 2022-2025

Department of Veterans Affairs

“Modeling New Therapeutic Approaches for Malignant Melanoma”

Project period direct funds: \$710,000.

The goals of this grant are 1) To determine the mechanism by which RGS induces expression of CD40 on tumor cells and to characterize the role of tumor cell CD40 in restoring response to ICI in immunocompetent mouse models of melanoma. 2) To evaluate whether addition of a CD40 agonist antibody will enhance sensitivity of melanoma tumors to RGS + ICI and define mechanisms of response using mouse models and human organoid co-culture systems. Tumoral, immune, and transcriptome changes will be evaluated through multicolor flow cytometry and single cell(sc) RNAseq analysis to provide mechanistic insight on how this combined therapy modulates response to therapy. 3) To determine whether RGS combined with a CXCR1/2 antagonist, can re-sensitize melanoma tumors to ICI therapy using similar approaches as for Aim 2. Significance: These studies will result in new therapeutic approaches to improve treatment of metastatic melanoma in our Veterans by enhancing response to ICI therapies or re-sensitizing ICI-resistant tumors to treatment with ICI.

CA243326 A1-01 (PI Richmond) 09/01/2019-8/31/2024

NIH/NCI:

Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway

Project period Direct Funds: \$1,259,925 direct costs

This proposal seeks to develop new combinations of treatment for patients with breast cancers. We will determine whether drugs that alter the tumor immune microenvironment can be used to make tumors that do not respond to immune checkpoint inhibitors responsive. If successful, these combined treatments will prolong the survival of breast cancer patient.

CA116021 (PI Richmond) 04/01/2020-03/31/2025

NIH/NCI

“New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors”.

Project period Direct Funds: \$1,305,000

The goals of this grant are to evaluate targeted therapies in combination with immune checkpoint inhibitors using mouse models, humanized PDX melanoma tumor models, and organoid co-culture models.

1U01TR002383-01 (Wiksw) 02/01/2018-01/31/2023

Harnessing human brain and liver micro physiological systems for testing therapeutics for metastatic melanoma

Project period Direct Funds : NIH \$1,345,430

This project will study how the tissue microenvironment affects the growth of metastatic melanoma cells and their response to drugs by using the Vanderbilt neurovascular unit tissue chip, the Pittsburgh liver-on-chip, and the Wisconsin engineered organoids for brain and liver, each of which includes multiple cell types.

Role: Co-Investigator

Vanderbilt Ingram Cancer Center P3 Catalyst Award 05/01/2023-4-30-2024

Rigosertib and Pembrolizumab in Anti-PD-1 Refractory Melanoma

Project Total Direct Costs: \$75,000

The goal of this study is to perform correlative studies on blood and tumor biopsy samples from melanoma patients entering our clinical trial to investigate the effect of combined rigosertib and pembrolizumab for patients who are refractory to anti-PD-1 therapy NCT05764395..

Role: Co-Investigator

1R37CA233770-01 (PI: Vilgelm) NIH/NCI 09/01/2018-08/31/2025

Combining senescence-inducing and senolytic agents to improve melanoma therapy. The specific aims of this project are 1) evaluate anti-melanoma efficacy of senescent-inducing and senolytic therapy, 2) define mechanisms of innate immune activation by senescent-inducing and senolytic therapy and 3) determine if senescent-inducing and senolytic therapy sensitizes melanoma to ICIs.

Role: Co-Investigator

1R01CA266767-01A1 (PI; John Wilson) 07/01/2022-06/30-2027

Engineering Vaccines for Neoantigen Targeted Cancer Immunotherapy

The objective of this application is to engineer neoantigen based vaccines for cancer immunotherapy.

Role: Consultant

1 R01 EB033822-01 (PI: John Wilson) 09/01/2022-08/31/2027

RIG-I Activating Nanoparticles for Immunopotential

The objective of this application is to optimize and advance RANs as a versatile platform for pharmacological activation of RIG-I.

Role: Consultant

PAST FUNDING: Brief Summary

NIH Individual NSRA, 1981-1983

NCI, CA34590, Chemokine Studies, 1983-2019. CA34590 (PI, Richmond), 20% effort. ARRA Supplement: 2009-2011.

NCI, CA56704, Transcriptional Regulation of MGSA Genes, 1992-2003

VA Merit Award, Studies on MGSA, 1983-2016

Associate Career Scientist Award, DVA, 1988-1999

American Cancer Society Grant Awarded, but turned down, 1988-1990

American Cancer Society Grant, 1991-1992

NCI, Pilot Studies on the Cancers Associated with AIDS, Supplement to the Vanderbilt Cancer Center Award, 1997-1999

Keloids in African Americans: an Altered Wound Healing Model, 1996-1999, Department of Veterans Affairs (CoPI's Ann Richmond and Shirley Russell-Meharry Medical School); 5% effort.

The Role of Chemokines in Wound Healing and Sepsis, 1998-2001. Department of Veterans Affairs and Department of Defense; (PI Ann Richmond,); 12% effort.

Utilization of Inhibitors of NF- κ B and Proteasome Inhibitors to block Melanoma Tumor Growth. \$30,000 direct costs, Vanderbilt Ingram Cancer Center Pilot Project, August 2001 to July 1, 2002.

Pilot Project on the GRECC Award: \$50,000/yr. for two years for studies on Chemokine Receptors on Endothelial Cells.

The utilization of PS-341 and PS-1145 to inhibit the growth of melanoma tumors. Millennium Pharmaceuticals, 2002-2003.

Skin Disease Research Center, National Institutes of Health, Director of the Molecular Genetics Core (1990-1995)

Molecular mechanisms of chemokine receptor sequestration. Department of Veterans Affairs, HBCU 2002-2005. Joint with Ricardo Richardson, Meharry Medical College

Development of an in vivo breast cancer model that permits interrogation of CXCR4 signaling pathways. Lilly Clinical Partners. 2003-2004.

PS-341 in Hepatocellular Carcinoma: A Phase II Trial. (Co-investigator, J Berlin-PI)
CA 099269-01A1. 2003-2006.

Inhibition of NF- κ B Signaling in Melanoma Therapy. Jeff Sosman, PI, Ann Richmond (Co- PI).
FDA Clinical studies of safety and effectiveness of Orphan Products. 2003-2006.

“SNRP Project at Meharry Medical College” NIH SNRP U54NS41071 9/1/06 to 8/31/11
(H K Rucker, PI, Ann Richmond, Co-Investigator)

“Molecularly Based Targeted Therapy for Melanoma” V Foundation Translational Grant:
(Ann Richmond and Jeff Sosman, Co PIs) 11/01/06 to 10/31/10.

The role of NIK in Melanoma Tumorigenesis: National Cancer Institute: 2005-2011, PI (Richmond)

W81XWH-11-1-0413 (Raman, Co-I, Richmond) 07/11 – 04/14 0.18 calendar mo
Department of Defense. A co-activator role for chemokine-dependent nuclear translocated LASP-1 in breast cancer

NCI P30 CA068485 Vanderbilt Ingram Cancer Center PDX Supplement: (Richmond Project leader)
10/1/2016-9/30/2018 NIH/NCI \$750,000 total costs “PDX Models for Melanoma”

VUMC sub- U24 (Manning/Richmond) 03/01/2018-02/23/2020 .20 calendar months NIH
Vanderbilt University, PET Imaging Resource, to \$39,033/yr.

Enhance Delivery of Individualized Cancer Therapeutics (VU-PREDICT)

We are proposing to characterize 10 colon cancer patient derived xenografts (PDXs) and with regard to their response to treatment with the glutaminase inhibitor CB839 and the EGFR inhibitor, panitumab in humanized mouse models.

5P30 CA068485-16 (Pietenpol) (Richmond, Assoc Director for Education) 09/20-8-2025 1.2 calendar mo
NIH/NCI \$3,781,250/year direct

“Vanderbilt-Ingram Cancer Center Core Support Grant”

The major goals of this project are: 1) Coordinate and integrate the cancer and cancer-related activities of Vanderbilt. 2.) Conduct, support and enhance cancer research and integrate cancer-related research throughout the University. 3.) Integrate, develop and conduct cancer education programs. 4.) Coordinate and integrate the care of cancer patients at Vanderbilt University Medical Center and the Veterans Administration Medical Center.

CA06845 CURE Supplement: (Richmond, Project leader) 10/1/2016-9/30/2021

NIH/NCI, \$79,000 direct/yr. “The Vanderbilt-Ingram Cancer Center: Discover Cancer Research Program for High School and Undergraduate Students

VA Merit Award 101BX002301 (Richmond, PI), 2017-2022

Department of Veterans Affairs “Modeling New Therapeutic Approaches for Malignant Melanoma”

Project period direct funds: \$650,000.

The goals of this grant are 1) To examine the ability of rigosertib alone or combined with CDK4/6 inhibitors to halt the growth of melanoma in immune competent mouse models, including nRAS mutant, BRAF mutant and B16 melanoma. 2) To characterize the effectiveness of rigosertib alone or combined with CDK4/6 inhibitor in combination with antibodies to check-point inhibitors in immune competent mouse models of melanoma. 3) To evaluate the effectiveness of combining rigosertib and CDK4/6i with anti-PD1 or anti-CD137 for the treatment of melanoma patient derived xenografts using humanized mouse models.

IIDRP-16-001 (PI: Vilgelm) Breast Cancer Research Foundation; 05/31/2017-06/30/2020

CDK4/6 inhibition modulates tumor immune microenvironment to enhance response to immunotherapy

This project proposed to determine the dynamic response of immune microenvironment in breast tumors undergoing CDK4/6 inhibitor treatment.

Role: Co-Investigator

5 U54CA163072 (Pal, PI, Richmond, co-PI) 09/01/2021-08/31/2026 (I stepped down as PI in the fall of 2021)
NIH/NCI \$781,836/year direct \$5,917,115 T/project total

MMC, VICC & TSU Partners in Eliminating Cancer Disparities

Over the past few years, due to strong senior faculty leadership at both institutions, a structure for a partnership between Meharry Medical College and the Vanderbilt-Ingram Cancer Center is proposed. This application will provide a firm foundation for a formal Meharry/VICC/TSU partnership.

PUBLICATIONS:

Papers: (* indicates graduate student or postdoctoral fellow in Ann Richmond's lab)

1. **Richmond A** and Elmer WA. 1979. Purification of a mouse embryo extract component which enhances chondrogenesis in vitro. *Developmental Biology* 76:366-383. PMID6893034
2. Chawla RK, Lawson DH, **Richmond A**, Rudman D. 1980. Effect of plasma interalpha trypsin inhibitor and cancer-related glycoprotein EDC1 on phytohemagglutinin induced thymidine uptake in lymphocytes. *Cancer Research* 40:4187-4191. PMID6162547
3. Chawla RK, Slaer SM, Lawson DH, Murray TG, Schmidt R, Shoji M, Nixon DW, **Richmond A**, Rudman D. 1980. Elevated plasma and urinary guanosine 3':5' monophosphate and increased production rate in patients with neoplastic diseases. *Cancer Research* 40:3915-3920. PMID6258769
4. **Richmond A**, Lawson DH, Nixon DW, Stevens JS, Chawla RK. 1982. In vitro growth promotion in human-malignant melanoma cells by fibroblast growth factor. *Cancer Research* 42:3175-3180. PMID6212117
5. **Richmond A**, Lawson DH, Nixon DW, Chawla RK. 1983. Extraction of a melanoma growth-stimulatory activity from culture medium conditioned by the Hs0294 human melanoma cell line. *Cancer Research* 43:2106-2112. PMID6600964
6. Lawson DH, Black ML, Nixon DW, Tindal G, Barnes D, **Richmond A**, Faraj B, Camp V, Ali F, Rudman D. 1983. Evaluation of trans sphenoidal hypophysectomy in the management of patients with advanced malignant melanoma. *Cancer* 51:1541-1545. PMID6186359
7. **Richmond A**, Lawson DH, Nixon DW, Chawla RK. 1985. Characterization of auto stimulatory and transforming growth factors from human melanoma cells. *Cancer Research* 45:6390-6394. PMID3864531
8. **Richmond A**, Fine R, Murray D, Lawson DH, and Priest J. 1986. Growth factor and cytogenetic abnormalities in nevus and malignant melanoma cells. *Journal of Investigative Dermatology* 86:295-302. PMID3745955

9. **Richmond A** and Thomas HG*. 1986. Purification of melanoma growth stimulatory activity. *Journal of Cellular Physiology* 129:375-384. PMID3465735
10. Lawson DH, Thomas HG*, Roy RGB, Gordon D, Nixon DW, Chawla RK, and **Richmond A**. 1987. Preparation of a monoclonal antibody to a melanoma growth stimulatory activity released into serum free culture medium by Hs0294 malignant melanoma cells. *Journal of Cellular Biochemistry* 24:168-185. PMID3611199
11. **Richmond A** and Thomas HG*. 1988. Purification of Melanoma Growth Stimulatory Activity. (eds. R.C. Hickey, G.F.Saunders, D.S. Rivera). *1988 Yearbook of Cancer*. 34:585-587.
12. **Richmond A** and Thomas HG.* 1988. Melanoma growth stimulatory activity, a novel growth factor with a tissue distribution not restricted to melanoma tissue. *Journal of Cellular Biochemistry* 36:185-198. PMID3356754
13. Thomas HG*. and **Richmond A**. 1988. Immunoaffinity purification of melanoma growth stimulatory activity. *Archives of Biochemistry and Biophysics* 260(2):719-724.PMID3341763
14. Thomas HG.* and **Richmond A**. 1988. High-yield purification of melanoma growth stimulatory activity. *Molecular and Cellular Endocrinology*. 57:69-76.PMID3396757
15. **Richmond A**, Balentien E*, Thomas HG.*, Flagg G, Barton DE, Spiess J, Bordoni R*, Francke U, Derynck R. 1988. Molecular characterization of melanoma growth stimulatory activity, a growth factor structurally related to B-Thromboglobulin. *EMBO Journal* 7:2025-2033. PMID2970963; NIHMS288441; PMC454478
16. Priest J, Phillips C, Wang Y, **Richmond A**. 1988. Chromosome and growth factor abnormalities in melanoma. *Cancer Genetics and Cytogenetics* 35:253-262. PMID3141038; NIHMS&PMC n/a
17. Bordoni R*, Thomas HG*, **Richmond A**. 1989. Interaction of melanoma growth stimulatory activity with other growth factors and regulation of messenger RNA expression in melanoma cells. *Journal of Cellular Biochemistry*. 39:421-428. PMID2722970
18. Balentien E*, Han JH*, Thomas HG*, Wen D, Samantha AK, Zachariae CO, Griffin PR, Brachmann R, Wong WL, Matsushima K, **Richmond A**, Derynck R. 1990. Recombinant expression, biochemical characterization, and biological activities of the human MGSA/gro protein. *Biochemistry* 29:10225-10233. PMID2271650
19. Bordoni R*, Fine R, Murray D, **Richmond A**. 1990. Characterization of the autocrine role of MGSA in normal melanocytes and malignant melanoma. *Journal of Cellular Biochemistry* 44:207-219. PMID2095366
20. Baker NE, Kucero G, **Richmond A**. 1990. Nucleotide sequence of the human melanoma growth stimulatory activity (MGSA) gene. *Nucleic Acids Research* 18(21):6453. PMID2129556; PMC332569
21. Balentien E*, Mufson BE, Derynck R, **Richmond A**. 1991. Effects of MGSA/GRO alpha on melanocyte transformation. *Oncogene* 6:1115-1124. PMID1861861
22. Cheng QC, Han JH*, Thomas HG*, Balentien E*, **Richmond A**. 1992. The melanoma growth stimulatory activity receptor consists of two proteins. Ligand binding results in enhanced tyrosine phosphorylation. *Journal of Immunology* 148:451-456. PMID1729365
23. Tettelbach W, Nanney L, Ellis D, King L, and **Richmond A**. 1993. Localization of MGSA/GRO protein in cutaneous lesions. *Journal of Cutaneous Pathology* 20:259-266 PMID8366215

24. Jaffe GJ, **Richmond A**, VanLe, L, Cheng QC, Shattuck RL*, Wong F, and Roberts W. 1993. Expression of three forms of melanoma growth stimulating activity (MGSA)/Gro in human retinal pigment epithelial cells. *Investigative Ophthalmology & Visual Science* 34:2776-2785. PMID8344798
25. Shattuck RL*, Wood LD*, Jaffe GJ, and **Richmond A**. 1994. MGSA/GRO transcription is differentially regulated in normal pigmented epithelial cells and melanoma cells. *Molecular and Cellular Biology* 14:791-802. PMID8264646; PMC358427
26. Mueller SG*, Schraw W, and **Richmond A**. 1994. Melanoma growth stimulatory activity enhances the phosphorylation of the class II interleukin-8 receptor in non-hematopoietic cells. *Journal of Biological Chemistry* 269: 1973-1980. PMID8294449
27. Mueller SG*, Schraw W and **Richmond A**. 1995. Activation of protein kinase C enhances the phosphorylation of the type B interleukin-8 receptor and stimulates its degradation in non-hematopoietic cells. *Journal of Biological Chemistry* 270:10439-10448. PMID7737978
28. Wood LD* and **Richmond A**. 1995. Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity/GRO α gene requires both NF-kB and Novel Constitutive Factors. *Journal of Biological Chemistry* 270:30619-30626, 1995. PMID8530498
29. Schraw WP, **Richmond A**. 1995. Melanoma growth stimulatory activity signaling through the class II Interleukin-8 receptor enhances the tyrosine phosphorylation of Crk-associated substrate, p130, and a 70-kilodalton protein. *Biochemistry* 34:13760-13767, 1995. PMID7577968
30. Wood LD* and **Richmond A**. 1995. HMGI(Y) and Sp1 in addition to NF-kB regulate transcription of the MGSA/GRO α gene. *Nucleic Acids Research* 23:4210-4219, 1995. PMID7479086; PMC307364
31. Nanney L, Mueller SG*, Bueno R, Peiper SC, **Richmond A**. 1995. Distributions of melanoma growth stimulatory activity of growth-regulated gene and the interleukin-8 receptor B in human wound repair. *American Journal of Pathology* 147:1248-1260, 1995. PMID7485389; PMC1869526
32. Owens JD*, Strieter R, Burdick M, Haghnegahdar H, Nanney L, Shattuck-Brandt R*, and **Richmond A**. 1997. Enhanced Tumor Forming Capacity for Immortalized Melanocytes Expressing Melanoma Growth Stimulatory Activity/Growth Related Cytokine α and β proteins. *International Journal of Cancer* 73 94-103. PMID9334815
33. Shattuck RS*, and **Richmond A**. 1997. Enhanced Degradation of I-kB α Contributes to Endogenous Activation of NF-kB in Hs294T Melanoma Cells. *Cancer Research* 57:3032-3039. PMID923219
34. Mueller SG*, Schraw WP, White J, Lam V and **Richmond A**. 1997. Ligand induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl terminal domain of the receptor. *Journal of Biological Chemistry* 272:8207-8214. PMID9079638
35. Shattuck RL*, Wood LD*, **Richmond A**. 1997. Identification and characterization of an MGSA/GRO Pseudogene. *DNA Sequence* 7 (6): 379-386. PMID9524820
36. Yang W,* and **Richmond A**. 1997. Interruption of G protein-coupling in CXCR2 does not alter ligand binding, but eliminates ligand activation of GTP γ S binding, calcium mobilization, and chemotaxis. *Biochemistry* 36:15193-15200. PMID9398246
37. Tang T*, Owen JD*, Du J, Walker CL and **Richmond A**. 1998. Molecular cloning and characterization of a mouse gene with homolog to the Duffy-antigen receptor for chemokines. *DNA Sequence* 9: 129-143. PMID1052743

38. Nanney LB, Skeel A, Luan J*, Polis S, **Richmond A**, Wang MH, Leonard EJ. 1998. Proteolytic Cleavage and Activation of pro-Macrophage-Stimulating Protein and Upregulation of its Receptor in Tissue Injury. *J. Investigative Dermatology* 111:573-581, 1998. PMID9764835
39. Yang W*, Wang D*, and **Richmond A**. 1999. Role of clathrin-mediated endocytosis in CXCR2 sequestration, resensitization and signal transduction. *J. Biol. Chem.* 274:11328-11333. PID10196223
40. Devalaraja M*, Wang DZ*, Ballard DW, and **Richmond A**. 1999. Elevated constitutive IKK activity and IκBα phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GROα transcription. *Cancer Res.* 59:1372-1377. PMID10096573
41. Haghnegahdar H, Du J, Wang DZ*, Strieter R, Burdick M, Nanney LB, Cardwell N, Shattuck-Brandt R*, Price J and **Richmond A**. 2000. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. *J Leuko. Biol.* 67:53-62. PMID10647998; NIHMS49434; PMC2669312
42. Devalaraja R*, Nanney LB, Daniel T and **Richmond A**. 2000. Delayed wound healing in CXCR2 knock-out mice. *J. Invest. Derm.* 115:234-244. Erratum in: *J Invest Dermatol* 2000. Nov; 115(5); 931. PMID10951241; NIHMS49435; PMC2664868
43. Nirodi CS*, Devalaraja R*, Nanney LB, Arrendal S, Russell S, Trupin J, **Richmond A**. 2000. Chemokine/Chemokine receptor expression in keloid and normal fibroblasts. *Wound Repair and Regeneration* 8: 371-382. PMID11115149; NIHMS290749; PMC3140346
44. Wang D*, Devalaraja MN*, Yang W*, Liang P, Matusmoto K, Endo T, and **Richmond A**. 2000. MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. *Oncogene* 19:4647-4659. PMID11030154; NIHMS49436; PMC2667445
45. Addison CL, Daniel TO, Ehlert JE, Liu H, Burdick MD, Xue YY, Morris S, Buechi L, Walz A, **Richmond A**, Strieter RM. 2000. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine induced angiogenic activity. *J. Immunology.* 165:5269-5277. PMID11046061
46. Fan GH*, Yang W*, **Richmond A**. 2001. Identification of a motif in the carboxyl terminus of CXCR2 that is involved in adaptin 2 binding and receptor internalization. *Biochem* 40:791-800. PMID11170396; NIHMS49439; PMC2664867
47. Luan J*, Furata Y, Du J, Yu Y, and **Richmond A**. 2001. Developmental expression of two CXC chemokines, MIP-2 and KC, and their receptors. *Cytokine* 14:253-263. PMID11444905; NIHMS290761
48. Yang JM*, Luan J*, Yu Y, Li C*, DePinho R, Chin L and **Richmond A**. 2001. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase 4a/alternate reading frame. *Cancer Res.* 61:8150-8157. PMID11719444
49. Fan GH*, Yang W*, **Richmond A**. 2001. Phosphorylation-independent association of CXCR2 with the PP2A core enzyme. *J. Biol. Chem.* 276: 16960-16968 PMID11278485; NIHMS49440; PMC2666306
50. Nirodi C S*, NagDas S, Moon N, Gygi S, Hart J, Olson G, Nepveu A, Aebersold R, **Richmond A**. 2001. The role of CDP in the negative regulation of CXCL1 gene expression. *J. Biol. Chem.* 276(28):26122-31 PMID11371564; NIHMS49441; PMC2665279 (
51. Nirodi CS* and **Richmond A**. 2001. A role for poly (ADP-ribose) polymerase (PARP) in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. *J. Biol Chem.* 276: 9366-9374). PMID1112786; NIHMS290770; PMC3369623

52. Wang DZ*, **Richmond A.** 2001. Nuclear factor- κ B activation by the CXC chemokine, MGSAGRO - α , involves the MEKK1/p38 Mitogen-activated protein kinase pathway. *J Biol. Chem.* 276:3650-3659. PMID11062239; NIHMS49438; PMC2676351
53. Yang JM*, and **Richmond A.** 2001. Constitutive IKK activity correlates with NF- κ B activation in human melanoma cells. *Cancer Res.* 61:4901-4909. PMID11406569; NIHMS290778; PMC3140402
54. Yang JM*, Fan G-H*, Wadzinski BI, **Richmond A.** 2001. Protein phosphatase 2A interacts with and directly dephosphorylates Rel A. *J. Biol. Chem.* 276:47828-47833. PMID11591705; NIHMS49444; PMC2665282
55. Du J, Peiper S, Luan J*, Devalaraja R*, Daniel T and **Richmond A.** 2002. Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. *J. Leukoc. Biol.* 71: 141-153. PMID11781290; NIHMS49447; PMC2665273
56. Fan GH*, Yang W*, and **Richmond A.** 2002. Hsc/Hsp70 interacting protein (Hip) associates with CXCR2 and regulates the receptor signaling and trafficking. *J Biol Chem.* 277: 6590-6597 (PMID11751889; NIHMS49446; PMC2665275
57. Wang DZ*, Sai J*, Carter G*, Sachpatzidis A, Lolis E and **Richmond A.** 2002. PAK1 kinase is required for CXCL1-induced chemotaxis. *Biochemistry* 41:7100-7107. PMID12033944; NIHMS49424; PMC2668253
58. Dhawan P* and **Richmond A.** 2002. A novel NF- κ B-inducing kinase-MAPK signaling pathway up-regulates NF- κ B activity in melanoma cells. *J Biol Chem.* 277: 7920-7928 PMID11773061; NIHMS49423; PMC2668260
59. **Richmond A.** 2002. NF- κ B, chemokine gene transcription, and tumor growth. *Nature Reviews Immunology.* 2:664-674. PMID12209135; NIHMS49426; PMC2668257
60. Dhawan P*, Singh AB, Ellis D, **Richmond A.** 2002. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor- κ B and tumor progression. *Cancer Res.* 62:7335-7342. PMID12499277
61. Dhawan P*, and **Richmond A.** 2002. Role of CXCL1 in tumorigenesis of melanoma. *J Leuko Biol.* 72: 9-18. PMID12101257; NIHMS49425; PMC2668262
62. Fan GH*, Lapiere L, Goldenring J, **Richmond A.** 2003. Differential regulation of CXCR2 trafficking by Rab GTPases. *Blood* 101:2115-2124. (PMID12411301; NIHMS290780
63. Wang DZ* and **Richmond A.** 2003. Cell surface heparin sulfate participates in CXCL1-induced signaling. *Biochemistry* 42: 1071-1077. PMID12549928; NIHMS49429; PMC2667446
64. Milatovic S, Nanney LB, Yu Y, White JR and **Richmond A.** 2003. Impaired healing of nitrogen mustard wounds in CXCR2 null mice. *Wound Repair and Regeneration* 11 (3) 213-219. PMID12753603; NIHMS49430; PMC2667443
65. Yang J* and **Richmond A.** 2004. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. *Molecular Therapy* 9: 846-855. PMID15194051; NIHMS49412; PMC2668261
66. Fan GH, Sai J, Lapiere L, Goldenring J and **Richmond A.** 2004. Rab11- family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis. , and the receptor-mediated chemotaxis. *Mol Biol Cell* 15:2456-2469. (PMID15004234; NIHMS49432; PMC404037

67. Amiri K, Horton L, LaFleur B, Sosman J, **Richmond A**. 2004. Augmenting chemo sensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (Velcade™, PS-341) as a therapeutic agent for malignant melanoma. *Cancer Res.* 64: 4912-4918. PMID15256463
68. Sai J, Fan GH, Wang D, and **Richmond A**. 2004. The C-terminal domain LLKIL motif of SCSR2 is required for ligand mediated polarization of early signals during chemotaxis. *J Cell Science* 117: 5489-5496. PMID15479720; NIHMS49414; PMC2668248
69. Walker G, Sai J, Chang C, **Richmond A**, and Wiksw J. 2005. Effects of flow and diffusion on chemotaxis studies in a microfabricated gradient generator. *Lab on a Chip.* 5: 611-618 *With Cover Photo*. PMID15915253; NIHMS49416; PMC2665276
70. Su YJ, Raghuvanshi SK, Yu Y, Nanney LB, Richardson MR and **Richmond A**. 2005. Altered CXCR2 signaling in β -arrestin-2 deficient mice mouse models. *J Immunology* 175: 5369-5402. PMID16210646; NIHMS49419; PMC2668249
71. Yang J, Amiri KI, Burke JR, Schmid JA, **Richmond A**. 2006. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. *Clin Cancer Res.* 12: 950-960. *With Cover Photo*. PMID16467110; NIHMS49420; PMC2668250
72. Wang DZ, Wang H, Brown J, Daikoku T, Ning W, Shi Q, **Richmond A**, Streiter R, Dey SK, Dubois R. 2006. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. *J Exp Med*: 203: 941-951. PMID16567391; NIHMS49422; PMC2118273
73. Sai J, Wiksw J, **Richmond A**. 2006. The IL sequence in the LLKIL motif in CXCR2 is required for full ligand-induced activation of Erk, Akt, and chemotaxis in HL60 cells. *J Biol Chem* 281: 35931-41. PMID 16990258; NIHMS49401; PMC2950015
74. Amiri K and **Richmond A**. 2006. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly (ADP-ribose) polymerase-1. *Oncogene* 25: 7714-7722. PMID16799643; NIHMS49400; PMC2665274
75. Ueda Y*, Neel NF*, Schutyser E*, Raman D*, **Richmond A**. 2006. Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. *Cancer Res.* 66: 5665-5675. PMID16740704; NIHMS49399; PMC2664111
76. Lee J, Wurfel M, Matute-Bello G, Frevert C, Rosengart M, Ranganathan M, Wong V, Holden T, Sutlief S, **Richmond A**, Peiper S, Martin T. 2006 The Duffy antigen modifies systemic and local tissue chemokine responses following LPS stimulation. *J Immunol* 177: 8086-8094. PMID17114483; NIHMS49402; PMC2665269
77. Ueda Y*, Su Y*, **Richmond A**. 2007. CAAT displacement protein regulates NF-kB-mediated chemokine transcription in melanoma cells. *Melanoma Research* 17:91-103. PMID17496784; NIHMS49406; PMC2665270
78. Yang *JM, Su YJ*, **Richmond A**. 2007. Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kB pathway. *Free Radical Biology and Medicine* 42: 1369-1380.. PMID17395010; NIHMS21364; PMC1905840
79. Yang J*, Pan W, Clawson GA, **Richmond A**. 2007 Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. *Cancer Research*, 67:3127-3134. PMID17409419; NIHMS49404; PMC2665271
80. Miller-Kittrell MS, Sai J*, Penfold M, **Richmond A**, Sparer TE. 2007. Functional characterization of chimpanzee cytomegalovirus chemokine, vCXCL-1^{ccmv}. *Virology* (364:454-465.

PMID17433398; NIHMS49405; PMC2665277

81. Neel NF*, Lapierre LA, Goldenring JR, **Richmond A**. 2007. RhoB plays an essential role in CXCR2 sorting decisions. *J Cell Science*. 120: 1559-1571. PMID17405813; NIHMS49403; PMC 2766565

82. Schutyser E*, Yu Y, Su Y*, Van Damme J, **Richmond A**. 2007. Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. *Eur J Immunol* 18: 59-70. PMID17594938; NIHMS49407; PMC2665278

83. Kantrow SM, Boyd AS, Ellis DL, Nanney LB, **Richmond A**, Shyr Y, Robbins JB. 2007. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. *J Cutan Pathol* 34: 593-596. PMID17640227; NIHMS49408;PMC2665272

84. Horton LW, Zaja-Milatovic S, Yu Y, Strieter RS, **Richmond A**. 2007. Opposing roles of murine duffy antigen receptor of chemokine and murine CXCR2 chemokine receptor-2 receptors in murine melanoma tumor growth. *Cancer Res*. 67:9791-9799. PMID17942909; NIHMS49409; PMC2668258

85. Yu Y, Su Y*, Opalenik SR, Neel NF*, Zaja-Milatovic S, Sai J*, **Richmond A**. 2008. Short Tail with Skin Lesion Phenotype Occurs in Transgenic Mice with Keratin-14 Promoter-Directed Expression of Mutant CXCR2. *J Leuk Biology* 84: 406-419. PMID18505935; NIHMS290790; PMC2493076

86. Sai J*, Raman D, Liu Y, Wiksw J, **Richmond A**. 2008 Parallel phosphatidylinositol 3-kinase (PI3K)- dependent and Src-dependent pathways lead to CXCR2-mediated Rac2 activation and chemotaxis.. *J Biol Chem*. 283: 26538-47..PMID18662984; NIHMS290791; PMC2546539

87. Dhawan P, Su Y*, Yu Y, Sobolik-Delmaire T*, Kelly M, Ellis DL, Cheung TC, Ware CF, **Richmond A**. 2008. The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. *J Biol Chem*. 283 15339-15408. PMID18347013; NIHMS49411; PMC2397477

88. Liu Y, Sai J*, **Richmond A**, and Wiksw J. 2008. Microfluidic Switching System for Analyzing Chemotaxis Responses of wortmannin-inhibited HL-60 cells. *Biomedical Devices* 10: 499-507. PMID18205049; NIHMS49410; PMC2668251

89. **Richmond A**. 2008. CCR9 Homes Metastatic Melanoma Cells to the Small Bowel. *Clinical Cancer Research*. 14: 621-623. PMID18245518

90. Yang J*, Zaja-Milatovic S, Thu Y*, **Richmond A**. 2009. Molecular determinants of melanoma malignancy; selecting targets for improved efficacy of chemotherapy. *Mol Cancer Therapy*. 8: 636-647. PMID19276165; NIHMS286886; PMC3140401

91. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, **Richmond A**, Lin CP, Moses HL. 2008 Abrogation of TGF β signaling in mammary carcinomas recruits myeloid immune suppressor cells that promote metastasis. *Cancer Cell* 13: 23-35 PMID18167337; NIHMS37354; PMC2245859

92. Baugher PJ* and **Richmond A**. 2008. The carboxyl-terminal PDZ ligand motif of chemokine receptor CXCR2 modulates post-endocytic sorting and cellular chemotaxis. *J Biol Chem*, 283: 30868-78. PMID18755694; NIHMS291800; PMC2576544

93. **Richmond A** and Su Y*. 2008 Mouse xenograft models vs GEM models for human cancer therapeutics. *Dis Models Mech*, 1: 78-82. PMID19048064; NIHMS291801; PMC2562196

94. Pruenster M, Mudde L, Bombosi P, Dimitrova S, Zsak M, Middleton J, **Richmond A**, Graham G, Segerer S, Nibbs R, and Rot A. 2009 *The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity*. *Nature Immunology* 10: 101-108 []. PMID19060902; NIHMS291803; PMC3205989

95. Neel NF*, Barzik M, Raman D, Sobolik-Delmaire T*, Sai J*, Ham AJ, Mernaugh RL, Gertler FB, and **Richmond A.** 2009. VASP is a CXCR2-interacting Protein that Regulates CXCR2-mediated Polarization and Chemotaxis, *J Cell Science*. 122: 1882-1894. PMID19435808; NIHMS291805; PMC2684839.
97. Pruenster M, Dimitrova S, Middleton J, Richmond A, Graham G, Segerer S, Nibbs R, Rot A. 2009. Duffy antigen/receptor for chemokines transports chemokines and supports their pro-migratory activity 'in vitro' and 'in vivo'. *Eur J Clin Invest* 39:23-4.
98. Su Y*, Amiri KI*, Horton LW, Yu Y, Ayers GD, Gregory E, Kelley MC, Puzanov I, **Richmond A**, and Sosman JA. 2010. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, anti-tumor effects, and modulation of therapeutic targets. *Clin Cancer Res*. 2010 Jan 16: 348-357. PMID20028756; NIHMS291806; PMC3205975
99. Das ST, Gangavarappu P, Rajagopalan L, Guerrero-Plata A, Garofalo RP, Sai J*, **Richmond A**, and Rajarathnam K. 2010. An essential role for CXCL8 dimer in neutrophil recruitment and function *Plos One*, 5(7): e11754. PMID20668677; PMC2909905.
100. Gruver JS, Potdar AA, Jeon J, Sai J*, Anderson B, Webb D, **Richmond A**, Quaranta V, Cummings PT, Chang CY. 2010. Bimodal analysis reveals a general scaling law governing nondirected and chemotactic cell motility. *Biophysics J*. 99 (2), 367-76. PMID20643054; NIHMS329025; PMC2905119
101. Raman D, Milatovic S-Z, Milatovic D, Fan GH, **Richmond A.** 2011. Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor1alpha suppress amyloid beta-induced neurotoxicity. *Toxicology and Applied Pharmacology* 2011 Nov 1:256(3) 300-313. PMID21704645; NIHMS305137; PMC3236026
102. Rhodes LV, Short S, Neel N, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow M, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Dent P, Worthylake RA, Curriel TJ, Hung MC, **Richmond A** and Burow ME. 2011 Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. *Cancer Research* 2011 Jan 15; 71 (2): 603-613. PMID21123450; NIHMS291814; PMC3140407.
103. Thu YM, Su YJ, Yang J, Splittgerber R, Na S, Boyd A, Mosse C, Simons C and **Richmond A.** 2011. NF- κ B inducing kinase (NIK) modulates tumorigenesis by regulating expression of pro-survival factors through the β -catenin pathway. *Oncogene*. May 17, 31 ;(20)2580-92. PMID21963849; NIHMS319712&336066; PMC3253179
104. Neel NF*, Sai J, Ham AJ, Sobolik-Delmaire T*, Mernaugh RL, **Richmond A.** 2011. IQGAP1 is a novel CXCR2-interacting protein and essential component of the "chemosynapse". *Plos One*. 6 (8) e23813, PMID21876773; NIHMS327660; PMC3158102
105. Hawkins OE and **Richmond A.** 2012. The dynamic Yin-Yang interaction of CXCR4 and CXCR7 in breast cancer metastasis. *Breast Cancer Research*, 1: 103. PMID22293321; PMC3496126
106. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, **Richmond A**, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. 2012. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. *PLoS One*: 4(7):e3530 PMID: 2253637 PMCID: PMC3335021
107. Yang J, Kantrow S, Sai J, Hawkins OE, Boothby M, Ayers GD, Young ED, Demicco EG, Lazar AJ, Lev D and **Richmond A.** 2012 INK4a/Arf Inactivation with Activation of the NF- κ B/IL-6 Pathway Is Sufficient to Drive the Development and Growth of Angiosarcoma. *Cancer Res* 18: 4682-4695 PMID 22835752. NIHMS397632; PMC3459678

108. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik-Delmaire T, Zaja-Milatovic S, Dahlman KD, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA and **Richmond A**. 2012. RAF265 inhibits the growth of advanced human melanoma tumors *Clinical Cancer Research* 18: 2184-2198, PMID22351689; PMCID; PMC 3724517
109. Liu Y, Hawkins OE, Su YJ, Vilgelm AE, Sobolik T, Thu Y, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC and **Richmond A**. 2013. Targeting aurora kinases limits tumor growth through DNA damage-mediated senescence and blockade of NF- κ B impairs this drug-induced senescence. *EMBO Mol Med*.4: 1-18. PMID23180582; PMC3569660
110. Raghuwanshi SK, Su Y, Singh V, Hayes K, Leung T, **Richmond A** and Richardson RM. 2012. The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. *J Immunol*. 6:2824-32, 2012 PMID22869904; NIHMS392618; PMC3436986
111. Crowder SW, Horton LW, Lee SH, McClain CM, Hawkins OE, Palmer AM, Bae H, **Richmond A** and Sung H-J. 2013. Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. *FASEB J*. 27:2788-98. PMID: 23568779; PMCID: PMC 3688746.
112. Davis TA, Vilgelm AE, **Richmond A**, Johnston JN. Preparation of (-)-Nutlin_3 using enantioselective organocatalysis at decagram scale. 2013. *J Org Chem*, 21: 10605-16, 2013 DOI: 10.1002/adsc.201. PMID: 24127627 PMCID: PMC3880828.
113. Raman D, Sai J, Hawkins OE and **Richmond A**. 2014. Adaptor protein2 (AP2) orchestrates CXCR2-mediated cell migration. *Traffic*.15:451-69. PMID: 24450359 PMCID: PMC 3966550.
114. Ciombor KK, Feng Y, Benson AB 3rd, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M, Amiri KI, **Richmond A** and Berlin J. 2014. A Phase II trial of Bortezomib plus doxorubicin in hepatocellular carcinoma. *Invest New Drugs*. 32: 1017-27. PMID: 24890858; PMCID: PMC4171216
115. Vilgelm AE, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart C, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN and **Richmond A**. 2015. Inhibition of aurora kinase sensitizes melanoma tumors to non-genotoxic p53 activation. *Cancer Res*. 75: 181-193 PMID: 25398437. PMCID: PMC4286469
116. Yang, J, Hawkins OE, Barham W, Gilchuk P, Boothby M, Ayers GD, Joyce S, Karin M, Yull FE and **Richmond A**. 2014. Myeloid IKK β promotes anti-tumor immunity by modulating CCL11 and the innate immune response. *Cancer Res*: 74: 727-84. PMID 225336190. PMC 4349570
117. Sobolik T, Su Y, Wells S, Ayers GD and **Richmond A**. 2014. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. *Mol Biol Cell*, 25: 566-82 PMID: 24403602; PMCID: PMC3937084.
118. Hockemeyer K, Janetopoulos C, Terekhor A, Vilgelm AE, Hofmeister W, Wikswo J and **Richmond A**. 2014. Design of a three-dimensional microfluidic device for interrogating cell-cell interactions in the tumor microenvironment. *Biomicrofluidics* 8 (4): 044105 (2014) [http://dx.doi.org/10.1063/1.4890330]. PMCID: PMC4189212
119. Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN and **Richmond A**. 2015. Mdm2 and aurora kinase A inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. *Cancer Res*. 75(1):181-93. PMID: 25398437. PMC 4286469
120. Sobolik T, Su Y, Ashby W, Schaffer DK, Wells S, Wikswo JP, Zijstra A and **Richmond A**. 2016. Development of novel murine mammary imaging windows to examine leukocyte trafficking and metastasis of mammary tumors with intravital imaging. *IntraVital*. 13: 5(1): e1125562 5:1, e1125562. DOI: 10.1080/21659087.2015.1125562.PMID: 28253517: PMC5226013.

121. Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC and **Richmond A**. 2015 Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. *Clin Cancer Res*.21: 5338-48. . PMID: 26152738 PMC 4668227.
122. Duvall-Noelle, Karwandyar A, **Richmond A** and Raman D. 2016. LASP-1-A nuclear hub for the AUHRF1-DNMT1-G9a-Snail1 complex. *Oncogene*. 35: 1122-33PMID: 25982273, PMC 4651668.
123. **Richmond A** and Yang J. 2015. The role of NF- κ B in modulating anti-tumor immunity. 2015. *Oncolmmunology*. 5 (1): e1005522. PMID: 26942050; PMC4760307.
124. Vilgelm AE and **Richmond A**. 2015. Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt anti-tumor immune responses. *Oncoimmunology*. 4(8):e1009299PMID: 26405565 PMC 4570092.
125. Sai J, Owens P, Novitskiy SV, Hawkins OE*, Vilgelm AE, Yang J, Sobolik T*, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M and **Richmond A**. 2017. PI3K inhibition reduces mammary tumor growth and metastasis and facilitates anti-tumor immunity and anti-PD1 responses. *Clin Cancer Res*: 16-2141. PMID: 28003307; PMC5479746.
126. Pawlikowski JS*, Brock C, Chen SC, Al-Olabi L, Nixon C, McGregor F, Paine S, Chanudet E, Lambie W, Holmes WM, Mullin JM, **Richmond A**, Wu H, Blyth KI, King A, Kinsler Val, Adams PD, Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling. *J Invest Dermatol*. 2015 135(8):2093-101 PMID: 25815427; PMC4539947.
127. Vilgelm AE*, Johnson CA*, Prasad N, Yang J*, Chen SC, Ayers GD, Pawlikowski JS*, Raman D*, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE and **Richmond A**. 2015. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. *J. Natl Cancer Inst.*; 108(6). pii: djv406. Print 2016 Jun. PMID: 26719346, PMC 4849355
128. Vilgelm AE* and **Richmond A**. 2016. Using Avatars to Win the Fight Over BRAF Inhibitor Resistance. *Pigment Cell and Melanoma Res*. 29: 398-9. DOI: [10.1111/pcmr.12473](https://doi.org/10.1111/pcmr.12473) PMID: 27185579.
129. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE*, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, **Richmond A**, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA and Balko JM. 2016. Melanoma-specific MHCII expression represents a tumor-autonomous phenotype and predicts response to anti-PD-1/PDL1 therapy. *Nature Communications* 7:10582.PMID: 2682283, PMC4740184
130. Saxon JA, Sherrill TP, Polosukhin VV, Sai J, Zaynagetdinov R, McLoed AG, Gulleman PM, Barham W, Cheng D-S, Hung RP, Gleaves LA , **Richmond A**, Young LR, Yull FE and Blackwell TS. 2016. Epithelial NF- κ B signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment. 2016. *Oncoimmunology*. 5: 6 e 1168549. Epub, March 30. DOI: 10.1080/2162402X.2016.1168549. PMID: 27471643 PMC: 4938365.
131. Pellom ST, Dudimah DF, Thounaojam MC, Uzhachenko RV, Singhai A, **Richmond A**, Shanker A. 2017. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. *Oncotarget*: 8:8604-8621. PMID: 28052005 PMC5352426.
132. Lavender N, Yang J, Chen S-C, Sai J, Johnson CA, Owens P, Ayers GD and **Richmond A**. 2017. The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. *BMC Cancer*, 17: 88.doi.10.1186/s12885-017-3074-2. PMID: 28143493 PMCID: PMC5286656
133. Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Johnson CA, Raman D, Higgins B, Bara BA, Johnston JN, Johnson DB, Kelley M, Chen S, Ayers GD and **Richmond A**. 2017. MDM2 antagonists counteract drug-induced DNA damage. *EBioMedicine*; doi: 10.1016/j.ebiom.2017.09.016. Epub 2017 Sep 19. PMID: 29030058. PMC 5652019.

134. Daniels AB, Froehler MT, Pierce JM, Nunnally AH, Calcutt MW, Bridges TM, LaNeve DC, Williams PE, Boyd KL, Reyzer ML, Lindsley CW, Friedman DL and **Richmond A**. 2018. Pharmacokinetics, tissue localization and toxicity in the first small animal (rabbit) model of intra-arterial chemotherapy for retinoblastoma. *Invest Ophthalmol Vis Science* 59: 446-454. PMID: 29368001, PMC 5783625.
135. Vilgelm AE, Saleh N, Riemenschneider K, Slesur L, Chen S-C, Johnston CA, Yang J, Shattuck-Brandt RL, Yan C, Johnson DB, El-Rohi RN, Halilovic E, Bosenberg M, Kauffmann RM, Hooks M, Kelley M, Ayers GD and **Richmond A**. 2019. Intrinsic resistance to CDK4/6 inhibition driven by cyclin D1-mediated compensatory activation of CDK1/2 is overcome by MDM2 antagonists. *Science Translational Medicine*. Aug 14, 11: (505), eaav7171.
137. Yang J, Kumar A, Vilgelm AE, Chen S-C, Ayers GD, Novitskiy SV, Joyce S and **Richmond A**. 2018. Loss of CXCR4 in myeloid cells enhances anti-tumor immunity and reduces melanoma tumor growth through NK cell and FASL-mediated mechanisms. *Cancer Immunology Research*.10:1186- 2018. PMID: 30108045 PMCID: PMC6170679
138. Rogers M, Sobolik T, Schaffer DK, Samson PC, Johnson AC, Owens P, Codreanu SG, Sherrod SD, McLean JA, Wikswa JP and **Richmond A**. 2018. Engineered microfluidic bioreactor for examining the three-dimensional breast tumor microenvironment. *Biomicrofluidics* 12: 12, 034102 (2018) PMID: 29774083 PMCID: PMC5938175.
139. **Daniels AB**, Froehler MT, Nunnally AH, Pierce JM, Bozic I, Stone CA, Santapuram PR, Tao YK, Boyd KL, Himmel LE, Chen SC, Du L, Friedman DL, **Richmond A**. Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach. *Invest Ophthalmol Vis Sci*. 2019 Mar 1;60(4):954-964. PMID: 30882851. PMC6424472
140. Ou, Yu-Chuan; Wen, Xiaona; Johnson, Christopher; Shae, Daniel; Ayala, Oscar; Webb, Joseph; Lin, Eugene; DeLapp, Rossane; Boyd, Kelli; **Richmond, Ann**; Mahadevan-Jansen, Anita; Rafat, Marjan; Wilson, John; Balko, Justin; Tantawy, Mohammed; Vilgelm, Anna; Bardhan, Rizia. 2020 "Multimodal Multiplexed Immunoinaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies" *ACS Nano*. 14:651-663. PMID: 31851488
141. Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, **Richmond A**. 2020. Metastatic melanoma patient-derived xenografts respond to MDM2 inhibition as a single agent or in combination with BRAF/MEK inhibition. *Clin Cancer Res*. 26:3803-3818, 2020.PMID: 32234759. PMC:7367743
143. Yang J, Yan C, Vilgelm AE, Chen SC, Ayers GD, Johnson CA, **Richmond A**. 2021. Targeted deletion of CXCR2 in myeloid cells alters the tumor immune environment to improve antitumor immunity. *Cancer Immunol Res*.9: 200-213. PMC7864868.
144. Williams CB, Nebhan CA, Yang J, Starnes LS, Yan C, Vilgelm AE, Chen SC, Dan Ayers G, Abramson V, Mayer IA, **Richmond A**. 2020. Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy. *Breast Cancer Treatment Reports*. Doi.org/10.1007/s10549-020-05846-5
145. Vilgelm AE, Bergdorf L. W, Bjartu, V. Shattuck-Brandt, RL, Bevins A, Jones C, Phifer C, Lee M, Lowe C, Boyd K, Nettekville J, Rhode S, Idrees K, Bauer J, Westover D, Reinfeld B, Baregamian N, **Richmond A**, Rathmell K, Lee E, McDonald OG, Weiss VL. 2020. Fine-Needle Aspiration-Based Isolation of Patient-Derived Cancer Organoids. *iScience* 23L101408 PMC7415927.
146. Yan C, and **Richmond A**. 2020. Th9 and Th17 cells: the controversial twins in cancer immunity. *J Clin Invest* .doi.org/10.1172/JCI1138418. PMID: 32484457.

147. Saleh N, Blevins A, Lawrence H, Uzhachenko R, Bharty V, Oghumu S, Shen C, Arteaga C, **Richmond A**, Vilgelm AE. 2020. Treatment with CDK4/6 inhibitor suppresses antigen-presenting cells and limits immunotherapy response in breast cancer models. Submitted.
148. Carley M. Bogan, Janene M. Pierce Stephanie Doss; Yuankai K. Tao, Sheau-chiann Chen, Kelli L. Boyd, Albert Liao, Terry Hsieh, David H. Abramson, Jasmine H. Francis, Debra L. Friedman, **Ann Richmond**, Anthony B Daniels. 2021. Intravitreal Melphalan Hydrochloride vs Propylene Glycol-free Melphalan for Retinoblastoma Vitreous Seeds: Efficacy, Toxicity and Stability in Rabbits Models and Patients. *Exp Eye Res* 204: 108439. PMC:8117559.
149. Kurley SJ, Tischler V, Bierie B, Novitskiy SV, Noske A, Varga Z, Zurrer-Hardi U, Brandt S, Carnahan RH, Cook RS, Muller WJ, **Richmond A**, Reynolds AB. 2020. Pulmonary metastasis of invasive ductal breast cancer is dependent on p120-catenin. *J Cell Science* 134: (6):jcs250639, PMID:33097605.
150. Yan*C, Saleh N, Yang J, Nebhan CA*, Vilgelm AE*, Reddy EP, Roland JT, Johnson DB, Chen S-C, Shattuck-Brandt RL, Ayers GD, **Richmond A**. 2021. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. *Molecular Cancer*, 20 (1): 85. PMC8182921.
151. Uzhachenko R, Bharti V, Ouyang, Z; Blevins A, Mont S, Saleh N, Lawrence H, Shen, Chen S, Ayers GD, DeNardo D, Arteaga C, **Richmond A**, Vilgelm AE. 2021. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. *Cell Reports* 6:35(1): 108944. PMID: 33826903
152. Yan, Chi*; Yang, Jinming; Saleh, Nabil; Chen, Sheau-Chiann; Ayers, Gregory; Abramson, Vandana; Mayer, Ingrid; **Richmond, Ann**. 2021. "Inhibition of the PI3K/mTOR pathway in breast cancer to enhance response to immune checkpoint inhibitors" 2021. *Int J Mol Sci May14:22(10):5207*. PMC8156389.
153. Bogan CM, Kaczmarek JV, Pierce JM, Chen SC, Boyd KL, Calcutt MW, Bridges TM, Lindsley CW, Nadelmann JB, Liao A, Hsieh T, Abramson DH, Francis JH, Friedman DL, **Richmond A**, Daniels AB. 2022. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study. *Br J Ophthalmol*. 106:288-296. PMC:8788260.
154. Kaczmarek J, Bogan CM, Pierce J, Tao YK, Chen S-C, Liu Q, Liu X, Boyd K, Calcutt MW, Bridges TM, Lindsley C, Friedman DI, **Richmond A**, Daniels AB. 2021. Intravitreal HDAC Inhibitor, Belinostat, Effectively Eradicates Vitreous Seeds Without Retinal Toxicity in Vivo in a Rabbit Retinoblastoma Model. *Invest Ophthalmol & Visual Sci*. 62:8. PMC:8590161.
155. Yan C and **Richmond A**. 2021. Hiding in the dark: Pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy. *Molecular Cancer* 20(1):146. PMC:8582157.
156. Daniels AB, Froehler MT, Kaczmarek JV, Bogan CM, Santapuram PR, Pierce JM, Chen SC, Schremp EA, Boyd KL, Tao YK, Calcutt MW, Koyama T, **Richmond A**, Friedman DL. 2021. Efficacy, toxicity and pharmacokinetics of intra-arterial chemotherapy versus intravenous chemotherapy for retinoblastoma in animal models and patients. *Transl Vis Sci Technol* 10::10. Doi:10.1167/tvst.10.11.10. PMC8431978.
157. Yan C*, Chen SC, Ayers GD, Nebhan CA*, Roland JT, Weiss VL, Johnson DB, **Richmond A**. Close proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients. 2021. *NJP Precis Oncol*.6:6 PMC8776860.
158. Pal T, Suiter SV, Moses HL, Smoot DT, **Richmond A**, Tiriveedhi V, Whalen MM, Adunyah SE. 2022. The Meharry-Vanderbilt-Tennessee State University Cancer Partnership (MVTCP): History and Highlights of 20 years of accomplishments. *J Health Care Poor Underserved*. 33: 419-436. PMC9319115.

159. Ngwa V, Edwards D, Hwang Y, Yan C, **Richmond A**, Brantley-Sieders D, Chen J. Loss of vascular endothelial glutaminase inhibits tumor growth and metastasis and increases sensitivity to chemotherapy. *Cancer Res Commun*, 2022. 2(7):694-705. PMC9645801.

160. Lihong Wang-Bishop, Mohamed Wehbe, Lucinda E. Pastora, Jinming Yang, Kyle M. Garland, Kyle W. Becker, Carcia S. Carson, Justin Song, Katherine Gibson-Korley, David Ulkoski, Olga Fedorova, Venkata Krishnamurthy, **Ann Richmond**, Anna Marie Pyle, John T. Wilson. Lipid nanoparticle delivery of 5'-triphosphate stem-loop RNA activates RIG-I to enhance response to cancer immunotherapy. 2023. Nature Nanotechnology, submitted

161. Bharti V, Watkins R, Kumar A, Shattuck-Brandt RL, Mossing A, Mitra A, Shen C, Tsung A, Davies AE, Hanel W, Reneau JC, Chung C, Sizemore GM, **Richmond A**, Weiss VL, Vilgelm AE. BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. 2022. *Cell Rep*. 41: 111826. PMC10030045.

162. Kuman A, Ramani V, Bharti V, Bellan D, Saleh N, Uzhachenko R, Shen C, Arteaga CL, **Richmond A**, Reddy SM, Vilgelm AE, Dendritic cell therapy augments anti-tumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4T cell responses. *J ImmunoTherapy of Cancer*, 2023, 11(5):e006019. PMC10231009.

163. Chi Yan, Caroline Nebhan, Nabil Saleh, Rebecca Shattuck-Brandt, Sheau-Chiann Chen, Gregory D Ayers, Weiss, V, **Ann Richmond** and Anna E. Vilgelm, Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted and Immune Therapy Combinations for Melanoma. 2023. *Cancers* 15, 3695.

164. **Yang J**, **Bergdorf K**, **Yan C**, Luo W, Chen SC, **Ayers D**, Liu Q, Liu X, Boothby M, Groves SM, Oleskie AN, Zhang X, Maeda DY, Zebala JA, Quaranta V, **Richmond A***. CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth. *Mol Cancer*, 2023, 22:92. Doi.org/10.1186/s12943-023-01789-9. PMC10239119.

165. Bullock KK, Shattuck-Brandt R, Scalise C, Luo W, Chen S, Saleh N, Gonzalez-Ericsson, Sanders ME, Ayers GD, Yan C, **Richmond A**. Endogenous pAKT activity associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC. *Cancer Lett*, 2024: 586:21668. PMID: 38311054.

CHAPTERS/Reviews:

* indicates trainee in Ann Richmond's lab

1. **Richmond A**, Lawson DH, and Nixon DW. 1982. Release of an autostimulatory growth activity by human malignant melanoma cells. *Cold Spring Harbor Conference on Cell Proliferation: Growth of Cells in Hormonally Defined Media*. Vol. 9:885-897.

2. Chawla RK, Miller FW, Lawson DH, **Richmond A**, Nixon D, and Rudman, D.H. 1981. Urinary EDC1 as an immunodiagnostic agent in breast cancer. Workshop in Immunodiagnosis of Cancer Proceedings, NIH/EPA/NIOHS, Washington, D.C., 1981.

3. Lawson DH, **Richmond A**, Nixon DW, and Rudman D. 1982. Metabolic Approaches to Cancer Cachexia, *Annual Reviews of Nutrition* 2:277-302. PMID6212117

4. **Richmond A**, Thomas HG*, and Roy RGB. 1987. Separation of melanoma growth stimulatory activity and human type-alpha transforming growth factor. . In *Peptide Growth Factors* (eds. D. Sirbasku and D. Barnes). *Methods in Enzymology* 146:112-126. PMID3479673

5. **Richmond A** and Thomas HG* 1988. Melanoma Growth Stimulatory Activity-Isolation from Human Melanoma Tumors and Characterization of Tissue Distribution. In *Growth Regulation of Cancer*, edited by M.E. Lippman, UCLA Symposia vol. 74, Allan R. Liss, Inc., New York, p. 71.

6. Bordoni R*, Thomas HG* and **Richmond A.** 1989. Interaction of melanoma growth stimulatory activity with other growth factors and regulation of messenger RNA expression in melanoma cells. In *Growth Factors and Their Receptors: Genetic Control and Rational Application*. pp. 173-180.
7. **Richmond A.** 1991. Pathogenic role of growth factors in dermatology. *Seminars in Dermatology* (ed. R.M. Fine), (10)3, 246-255. PMID1931574
8. Thomas HG*, Han JH*, Balentien E*, Bordoni R* and **Richmond A.** 1991. Purification and characterization of recombinant melanoma growth stimulatory activity. *Peptide Growth Factors, Part C. Methods in Enzymology* (eds. D. Barnes, J.P. Mather, G.H. Sato). 198, 373-383.
9. **Richmond A.** 1991. Growth and differentiation in melanocytes. In *Molecular and Cellular Approaches to the Control of Proliferation and Differentiation* (eds. G.S. Stein and J.B. Lian), 269-295.
10. Shattuck RL*, Balentien EG*, **Richmond A.** 1991. Melanoma growth stimulatory activity -- A modulator of melanocyte proliferation, neutrophil chemotaxis, and tumor progression. In *Progress in Leukocyte Biology* 11:111-116.
11. **Richmond A.** 1996. MGSA/GRO proteins: Physiology, Biology, Structure/function, Role in Disease. *Chemokines* (CRC Press, Richard Horuk, editor), 87-124.
12. Luan J*, Shattuck-Brandt RS*, Haghnegahdar H, Owen JD*, Strieter R, Burdick M, Nirodi CS*, Beauchamp D, Johnson KN, **Richmond A.** 1997. Mechanism and biological significance of constitutive expression of the MGSA/GRO chemokines in malignant melanoma tumor progression. *J. Leukocyte Biol* 62:588-597. PMID9365113
13. Shattuck RL* and **Richmond A.** 1998. Melanoma Growth Stimulatory Activity. in *Human Cytokines. Handbook for Basic and Clinical Research*. Vol. III (ed. BB Aggarwal), pages 266-313
14. **Richmond A,** Mueller S*, White JR, Schraw WP. 1997. C-X-C chemokine receptor desensitization is mediated through ligand enhanced receptor phosphorylation on serine residues. In *Chemokines and Chemokine Receptors* (ed. R. Horuk) *Methods in Enzymology*, 288: 3-15. PMID9356983
15. **Richmond A,** Haghnegahdar H, Shattuck-Brandt R*, Wood LD*, Nirodi CS*, Owen JD*, Strieter R, Burdick M, Luan J*. 1999. The role of melanoma growth stimulatory activity in melanoma tumorigenesis and angiogenesis. In *Chemokines and Cancer*, Humana Press (ed BJ Rollins) pages 169-189.
16. **Richmond A,** Luan J *, Du J, Haghnegahdar H. 1999. The role of chemokines in wound healing and melanoma biology. In *Chemokines in Disease* Chapter 13: 191-214, Humana Press (ed. Caroline Hebert).
17. Devalaraja M*, Yang W* and **Richmond A.** 1999. Multiple chemotactic factors: fine control or redundancy. In *Trends in Pharmacological Sciences*, 236: 151-156. PMID10322500
18. **Richmond A,** Yang W* and Devalaraja MND*. 1999. Chemokine receptor signal transduction mechanisms. In *Chemokines and Allergic Disease*. (Ed. Marc Rothenberg), Marcel Dekker Inc. 15: 311-338.
19. Wang D* and **Richmond A.** MGSA/GRO. 1999. On-line Cytokine book. (Ed. J.J. Oppenheim), Academic Press, Chapter 9.
20. **Richmond A** and Kaempfer R. Cytokines revisited at Hilton Head: 2000. *Growth Factor and Cytokine Reviews* 11:255-266. PMID10817967
21. Amiri K* and **Richmond A.** 2003. Fine tuning the transcriptional regulation of the CXCL1 chemokine. *Prog Nuc Acids Res and Mol Biol.* 74: 1-36. PMID14510072; NIHMS49431; PMC3140403.

22. Fan GH* and **Richmond A.** 2004. Chemokine Receptors. *Encyclopedia of Biological Chemistry*. (W.J. Lennarz & M.D. Lane, eds) Elsevier, Oxford, Vol 1, pp 413-418.
23. **Richmond A**, Fan GH*, Dhawan P*, Yang J*. 2003. How do chemokine/chemokine receptor activations affect tumorigenesis? *Novartis Foundation Symposium*. 256:74-91. PMID15027484; NIH327653;
24. Schutyser E*, **Richmond A** and VanDamme Jo. 2005. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. *J Leuko. Biol.* 78: 14-26. PMID15784687; NIHMS49415; PMC2665283
25. Amiri KI* and **Richmond A.** 2005. Role of nuclear factor- κ B in melanoma. *Cancer and Metastasis Reviews* 24: 321-333. PMID15986139; NIHMS49417; PMC2668255
26. Neel NF*, Schutyser E*, Sai J*, Fan GH* and **Richmond A.** 2005. Chemokine receptor internalization and intracellular trafficking. *Growth Factor and Cytokine Reviews*: 368: 637-658. PMID15998596; NIHMS49418; PMC2668263
27. Ueda Y* and Richmond A. 2006. NF- κ B activation in melanoma. *Pigment Cell Res.* 19: 112-124. PMID16524427; NIHMS49421; PMC2668252
28. Baugher P* and Richmond A. 2007. CXC Chemokines. *Encyclopedia of Cancer*. (Ed Manfred Schwab, Springer-Verlag, NY,) pp 787-789.
30. Raman D, Baugher P,* Thu Y* and Richmond A. 2008. Role of chemokines in tumor growth. *Cancer Letts.* ePub July 11. 256: 137-165. PMID17629396; NIHMS32005; PMC2065851
31. Zaja-Milatovic S and **Richmond A.** 2008. CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. *Histol. Histopathol.* 23: 1399-1407. PMID18785122; NIHMS295022; PMC3140405
32. Yang J* and **Richmond A.** 2009. Monitoring NF- κ B mediated chemokine transcription in tumorigenesis. *Methods in Enzymology*, 460: 347-355. PMID19446734; NIHMS291823; PMC3140415
33. Raman D, Neel NF* and **Richmond A.** 2009 Characterization of chemokine receptor CXCR2 interacting proteins using a proteomics approach to define the CXCR2 "chemosynapse". Invited article for *Methods in Enzymology*, 15: 315-330. PMID19446732; NIHMS291825; PMC3140414
34. **Richmond A**, Yang J* and Su Y.* 2009. The good and the bad of chemokines/chemokine receptors in melanoma. *J Pigment Cell and Melanoma Res.* 22: 175-186 PMID19222802; NIHMS189486; PMC2848967
35. Wang D, Dubois R and **Richmond A.** 2009. The role of chemokines in intestinal inflammation and cancer. *Current Opinion in Pharmacology.* 9: 688-696. PMID19734090; NIHMS138266; PMC2787713
36. Lazennec G and **Richmond A.** 2010. Chemokines and chemokine receptors: New insights into cancer-related inflammation. *Trends in Mol Medicine.* 16:133-44. PMID20163989; NIHMS180246; PMC2840699
37. Thu Yee Mon* and **Richmond A.** 2010. NF- κ B inducing kinase: a key regulator in the immune system and in cancer. *Cytokine and Growth Factor Reviews*, 4: 213-26. PMID: 20685151; NIHMS2939163; PMC2939163
38. **Richmond A.** 2011. Chemokine research moves on. *Exp Cell Res*, 5: 553-555. PMID: 21241691; NIHMS266341; PMC3056356
39. Raman D, Sobolik-Delmaire T* and Richmond **A.** 2011. Chemokines in health and disease. *Exp Cell Res.* 5: 575-589. PMID: 21223965; NIHMS264758; PMC3063402

40. Sobolik-Delmaire T*, Raman D,* Sai J*, Fan GH*, and **Richmond A.** (2013) Chemokine Receptors. In: Lennarz, W.J. and Lane, M.D. (eds.) *The Encyclopedia of Biological Chemistry*, Vol. 3, pp. 480-485. Waltham, MA: Academic Press
41. Su Y* and **Richmond A.** Critical Review: Chemokine regulation of neutrophil infiltration of skin wounds. *Advances in Wound Care. (New Rochelle) 2015 Nov 1; 4(11):631-640. Review PMID: 26543677: PMC 4620531*
42. Sai J*, Hockemeyer K*, Rogers M*, Wikswo JP and **Richmond A.** Using microfluidics and microbio reactors to study chemotaxis and the microenvironment. (Ed. Tracy Handel) *Methods of Enzymology. 2016, 570: 19-45. PMID: 26921940. PMC: 5378165*
43. Vilgelm AE* and **Richmond A.** Combinatorial approach to cancer immunotherapy: strength in numbers. 2016. *J. Leuk Biol, 100: 275-90. PMID: 27256670. PMC:*
44. Nichols EE, **Richmond A** and Daniels AB. Tumor characteristics, genetics, management, and the risk of metastasis in uveal melanoma. 2016. *Seminars in Ophthalmol. 31: 304-309. [PMC5526754](#)*
45. Nichols EE, **Richmond A**, Daniels AB. Disparities in uveal melanoma: patient characteristic. 2016. *Seminars Ophthalmol.31: 296-303. PMID: 27128153I PMC5441550.*
46. Vilgelm AE* and **Richmond A.** Chemokine modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. 2019. *Frontiers in Immunology. 10: 333. PMC6400988.*
47. Luker G, Yang J * and **Richmond A.** Scala S, Festuccia C, Schottelius M, Wester HJ, Zimmermann J. At the Bedside: Profiling and Treating Patients with CXCR4-expressing Cancers". 2021. CXCR4 as a target for Cancer Therapy: Bedside to Bench, *J Leukocyte Biol, 109(5): 969-989. PMID: 33104270.*
48. Shoghi KI, Badea CT, Blocker Sj, Chenevert T,Laforest R, Lewis MT, Luker GD, Manning HC, Marcus DS, Mowery YM, Pickup S, **Richmond A**, Ross B, Vilgelm AE, Yankeelov TE, Zhou R. Co-Clinical Imaging Resource Program (CIRP):2020. Bridging the translational divide to advance precision medicine. *Tomography: 6:273-287. PMC7442091.*
49. Pataje G. Prasanna, PhD*, Deborah Citrin, MD, Jeffrey Hildesheim, PhD, Mansoor Ahmed PhD, Michael G. Espey, PhD, Sundar Venkatachalam, PhD, Gabriela Riscuta, MD, CNS, Dan Xi, PhD, Guangrong Zheng, PhD, Jan van Deursen, PhD, Jorg Goronzy, PhD, Stephen Kron, MD, PhD, Mitchell Anscher, MD, Ned Sharpless, MD, Judith Campisi, PhD, Stephen Brown, PhD, Laura Neiderhofer, MD, PhD, Ana O'Loughlen, PhD, Alexandros Georgakilas, PhD, Francois Paris, PhD, David Guis, MD, PhD, David Gewirtz, PhD, Clemens A Schmitt, MD, Mohamed Abazeed, MD, PhD, James Kirkland, MD, **Ann Richmond, PhD**, Paul Romesser, MD, Scott Lowe, PhD, Jesus Gil, PhD, Marc Mendonca, PhD, Sundeep Burma, PhD, Daohong Zhou, MD, and C.N. Coleman, MD. 2021. Therapy-Induced Senescence: Opportunities to Improve Anti-Cancer Therapy. 2021. *J Natl Cancer Society, 113: 1285-1298. PMC:338486333.*
50. Zhi Zhu Zhang* and **Ann Richmond.** The role of PI3K inhibition in the treatment of breast cancer, alone or combined with immune checkpoint inhibitors. 2021. *Front Mol Biosci. May 7, 8:648663 PMC:8139556.*
51. Bulloch K and **Richmond A.** Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the efficacy of immunotherapy. 2021. *CANCERS, 13:6293 PMC869924*
52. Zhang Z, **Richmond A**, Yan C. Immunomodulatory properties of PI3K/AKT/mTOR and MAPK/MEK/ERK inhibition augment response to immune checkpoint blockade in melanoma and triple-negative breast cancer. 2022. *Int J of Mol Sci 23 (13),7353,*
53. Lazannec G, Raharathnam K, **Richmond A**, CXCR2 chemokine receptor—a master regulator in cancer and physiology. 2023. *Trends Mol Med. 2024, 30:37-55. PMID: 37872025; PMCID: PMC10841707.*

54. Zhou Y, **Richmond A**, and Yan C. Harnessing the potential of CD40 agonism in cancer therapy. *Cytokine Growth Factor Rev.* 2024 Feb;75:40-56. doi: 10.1016/j.cytogfr.2023.11.002. Epub 2023 Dec 4. Review. PubMed PMID: 38102001; PubMed Central PMCID: PMC10922420.

ACADEMIC ACTIVITIES:

Vanderbilt University and Department of Veterans Affairs (Nashville) Committees

Search Committee, Gross Anatomy Position, 1989-90, Department of Cell Biology
Biomedical Sciences Internal Accreditation Review, 1991 and 1998
Biohazards Committee, VA Medical Center, 1991-present
VA Committee on Scientific Misconduct, 1993-1995
Standing Policy Committee for Biomedical Sciences, Vanderbilt University, 1992-1995
School of Medicine Advisory Council, Vanderbilt University, 1993 - 1996
Graduate Faculty Council, Vanderbilt University School of Medicine, 1993 - 1996; 2003-2005.
Secretary of the Vanderbilt Graduate Faculty Council, 1995-96.
Sigma Xi, Nominations Committee, Vanderbilt, 1993-95; Membership Committee 1996-97.
Graduate Advisory Council for Cell Biology, 1993-1995.
VUMS Library Collection Advisory Forum, 1996-1997.
University Faculty Senate, 1996-1999; PEAF Sub-Committee 1996-1999.
Department of Cancer Biology, Review Committee for Secondary Faculty, 2000-present
Consultative Committee for the Faculty Senate, 1999
Faculty Representative for the Cell Biology Advisory Committee to the Chair, 1998-2000
VUMC Discovery Grant Review Committee, 1999
University Appellate Review Board, 1999-2000
Dean's Committee for Conflict Resolution: 2000-2001
Committee on Mentoring Students and Postdoctoral Fellows not Native-Born English Speakers, 2000-2005
Department of Veterans Affairs Research and Development Committee, 2000-present
VUMC Tenure and Promotions Committee, 2000-2009. Co-Chair 2005-2007, Chair, 2007 -2009
Cancer Biology Search Committee, 2001-2003,
Faculty Reward Plan Advisory Committee, 1999-present, Committee Chair
Chair of Committee to Organize a Master's Degree in Laboratory Science, 2002-2004
Graduate Faculty Advisory Committee, 2003-present
Associate Director of Education for the Vanderbilt Ingram Cancer Center, 2004-present
Director of Graduate Studies for the MLS program, 2004-2005
Assistant Dean for Biomedical Research, Education and Training, 2005-2010
Research Integrity Officer, VA Medical Center, 2008-present
Strategic Planning Committee for Research at the VA, 2008-2009
Advisory Committee for Review of VA Research Career Scientist Awards, 2008-2012
Internal Advisory Committee for MMC-VICC-TSU Cancer Partnership, 2005-present
Executive Committee for the Vanderbilt Ingram Cancer Center, 2004-2020
Medical Center Tenure Review Committee, 2010-2013
Chair of Staff and Faculty Research Awards Committee, School of Medicine, 2009-2011
Search Committee for Chair of Cell and Developmental Biology, 2011-2012
Search Committee for Chair of Dermatology, 2015-2016
Search Committee for Director of the Bone Center, Department of Medicine, 2015-2016
Co-Chair of the Space Committee, VA Medical Center, 2015-2016
Search Committee Chair for Cancer Pharmacology faculty, 2018-present
VI4 Strategic Planning Committee, 2019-present
Search Committee for ACOS for R&D, Nashville, VA 2020
Deans Scientific Misconduct Committee: 2008-2010, 2016-2017, 2019, 2020.
Search Committee for Chair of Biochemistry: 2021
Vanderbilt Provost Review Committee for Seeding Success grants, 2022
VOLT T32 Advisory Committee 2017-present
VCORCDP K12 Advisory Committee: 2010-present

Search Committee for Leaders of the VICC Program in Cell Biology and Program in Genome Maintenance 2022-2024

Edge for Scholar VUMC Internal Study Section, 2022-present

Selection Committee for Vanderbilt Award for Women in Research, 2015-present

Department of Pharmacology, Search Committee, 2020

Ph.D. Dissertation Committee for: Joe Oozer, Ed Yang, Kurt Lang, Lin Manchung, Radhika Donald, Scott Eblen, Bob Carver, Lufen Chang, Mike Engel, Jo Lopez. Amelia Entingh, David Strayhorn, Brett Everhart, Permila Harrell, Mark Gustavson, Nikki Cheng, Sheng-Ru Shiou, Xiang Qi, Debbie Mariner, Nancy Dumont, Mike Davis, Mai Wang, Nicole Durcharme, Mai Wang, Amber Bowden, Li Yang, Nicole Fowler, Meridith Vaughn, Wei Fang, Laura DeBuske, YeeMon Thu, Laura Gordy, Alisha Russell, Kurt Watson, Dhananjay Sakrikar, Andrea Frump, Jennifer Reiner, Wendy He, Ganglei Zhang, Dawit Jowhar, Peter Vollbrecht, Xingyuan Lu, Jamie Osborn, Allyson McLoed, Keisha Hardeman, Katie Hutchinson, Whitney Rabacal, Spencer Crowder, David Austin, Deon Dixit, Ali Greenplate, Megan Capozzi, Carla Gibbs (Meharry Medical College), Portia Thomas (Meharry Medical College), Mark Crowder (Pharm), Zach Sandusky (CANB); Katie Hebron (CANB), Laura Kim (CANB), Jessalyn Baljon (BME), Ly Huong Pham (PMI), Eileen Shiuhan (CANB), Jenna Mosier (BME), Kennady Bulloch (Pharm); Matthew Jenkins (Pharm), Adam Miranda (CanB), Ebony Hargrove-Wiley (CanBI), Kensey Bergdorf (CanBI), Gosife Okoye (MD/PhD) Xiaopeng Sun (PMI) Wenjun Wang (BME), McKenzie Windham (BME); Nabil Salah (CDB), Carla Gibbs (Meharry), Ebony Hargrove-Wiley (CANB), Adam Miranda (CANB), Elizabeth Westcott (PMI)

Cell Biology Phase I Committee: Gail Ganzer, Jean Witty, Nancy Wall, Tom Polte, Kathy Heppner, Xione Zhang, Nathan Hedstrom, Ute Prilinger, Allen Adams, Alex Feltus, Dana Brantley, Debbie Mariner, Nancy Dumont, Mike Davis, Mai Wang, Nicole Durcharme, Nabil Saleh,

Cancer Biology Phase I Committee: Yelena Janumyan, Roger S Jackson, Yersenia Rivera, Andres Rojas, Kimberely Boelte, Eddie Nam, Carrie Whiting, Andreia Bates, Sora Lee, Jamie Osborn; Keisha Hardeman; Holli Loomans, Carla Gibbs (Meharry), Portia Thomas (Meharry); Eileen Shiuhan; Mark Crowder; Deon Dixit; Ally Greenplate; Vera Mayhew

Undergraduate Mentoring in the last 10 years: Kate Hockemeyer 2011-2013; Peter DelNero 2010-2011; Deepa Joshi 2008-2010; Zar Min, 2011; Shuai Yuan, 2010-2011; Tyesha Martin, 2012-2013; Jessica Smith, 2012; Carla Gibbs, 2013; Sesay Abraham, 2013. Matthew Rogers, 2013-2017, Kennady Bulloch, 2017-2018. Judy Min (2021-), Tiara Oldfield (2020-2021), ZhuZhi Zhang (2019-2021), Toran Kirkwood (2019-2020), Maggie Zhou (2022-present).

Additional Faculty Mentoring: K01 co-mentor for Magaly Martinez-Ferrer 2010-2014; Susan Opalenik, R21 2008-2010; Barbara Fingleton, Rebecca Ihrle, Amos Swake, Swarup Tirividee, Doek Son, Fiona Yull, Josie Eid, Ela Knapnik, Christy Osgood, Julie Sterling, Rebecca Cook, Phil Owens (VA CDA mentee), Shannon Arnold (VA CDA mentee), Anthony Daniels, M.D. (ocular oncology surgeon, mentor for K08 grant), John Wilson, Ph.D. (MRA Award and SU2C Award), Dolly A. Padovani-Claudio, M.D., Brent Ferrell (K23 Award); Rachel Bonami (Junior faculty, Rheumatology); Doug Johnson, MD (Hem/Onc); Rachelle Johnson; Erin Caprioli; Swarup Tiriveedhi (TSU); Deok-Soo Sun (Meharry);

MAJOR ACCOMPLISHMENTS AND HONORS:

Career Scientist Award, and Senior Career Scientist Award DVA 1988-2027

Director of Graduate Studies for the Department of Cell Biology, 1993-1995

Organizer of the First International Gordon Research Conference for Chemotactic Cytokines, 1994

Organizer and Director of the Master of Laboratory Science Program, 2004-2005

ELAM Fellow, 2002-2003

Assistant Dean for Biomedical Research, Education and Training, 2004-2010

Vice Chair of Department of Cancer Biology, 2000-2017

Ingram Professor of Cancer Biology, 2005-present

President Elect, Society for Leukocyte Biology, 2012-2014; President, 2014-2016.

Associate Director of Education, Vanderbilt Ingram Cancer Center, 2004-present

Director, Program in Cancer Biology, 2017-present
William S. Middleton Award Winner, 2016
Delores Shockley Partnership Award, 2018
Legacy Award Winner, 2019

TEACHING:

Vanderbilt University School of Medicine

- I. Cell Biology and Histology, 1990-1999. Lectures and Labs in the Urinary System. 3 hr lecture and Lab2 to 100 students
- II. Cell Biology 310 Core Course, 1990-1995. Lectures on G protein-coupled receptors, signal transduction and chemotactic cytokines. ~30 students, 5 hours lecture
- III. Cancer Biology Core Course, 2019-present. Lectures on Immunity and Cancer
- IV. Pharmacology Core Curriculum, 2019. Lectures on Cancer Cell Recognition and Immune Therapy
- V. Lecture to Medical Students, 2019. Immersion Studies in Cancer Biology
- VI. Grant Writing Course (CANB 5049). 2021-2023 Co-Director of Course
- VII. Biomedical Engineering Senior Design Project: 5 biomedical engineering students –one year project to build new bioreactors to study cancer cell/immune cell interactions. Co-taught with John Wikswo
- VIII. IGP Section on Signal Transduction: 2021 and 2022—One month of concentrated student interaction and teaching
- IX. Graduate Students Directed Study: 2-3 month rotations

Lauren Wood	1990	Transcriptional Regulation of MGSA.
Jiunn-Lin Wang.	1992	MGSA Receptor Expression in E.coli.
James Owen	1993	Characterization of the role of MGSA□ in transformation
Renee Combs	1995	Does the DARC receptor transduce a signal
Eric Dawson	1995	Site-directed mutagenesis of MGSA isoforms
Melanie Light	1995	Cloning of melanoma chemokine receptors
Anwell Chang	1995	PCR cloning of melanoma chemokine receptors
Jing Luan	1995	Regulation of expression of MGSA genes in human cancers
Lynn Sanderson	1995	Sp1/Sp3 involvement in MGSA/GRO transcription
Nikki Joiner	1997	Development of ELR mutants of MGSA/GRO
D-W Jo	1997	The role of Ras in the MGSA/GRO signal transduction pathway
Nicki Fox	1998	The role of NIK in the constitutive activation of NF-kB
Jesse Hart	1999	The characterization of the IUR-F in melanoma
Tammy Wingo	2000	The role of CXCR3 in antagonism of CXCR2
Alex Eshighian	2000	Transcriptional regulation of CXCL1
Roger Liu	2000	The role of AIK in CXCR2 signal transduction
Kathy Amiri	2001	The role of AKT in the regulation of transcription of CXCL1
Josh Rosenberg	2001	Model for angiogenesis and tumorigenesis
Amber Bowen	2002	Animal models for chemokine receptor studies
Nicole Fowler	2002	Chemokine receptor mediated cell polarization
Robin Marjorum	2004	Chemokine receptor expression in endothelium
Kurt Watson	2005	Chemokine receptor association with cyclophilin
Tiffany Johnson	2005	Chemokine receptor association with clathrin
Yuxiang Zheng	2005	Chemokine mediated alterations in gene expression
Mandy Mullins	2005	Chemokine regulated cell motility
Kelly Richardson	2005	Chemokine mediated signal transduction

- | | | |
|------------------|------|--|
| Maria Alfaro | 2006 | CXCR2 interaction with AIK |
| Yee Mon Thu | 2006 | CXCR4 expression in intestinal epithelial cells |
| Sarah Short | 2008 | CXCR4 in breast cancer metastasis |
| Katie Hutchinson | 2014 | Chromosomal translocations that activate BRAF in melanoma |
| Hillary Layden | 2018 | Wee1 and MDM2 antagonists with BRAF and MEK inhibitors in melanoma |
| Nabil Saleh | 2020 | Rigosertib resistance mechanisms in melanoma |
| Kennady Bullock | 2021 | AKT inhibitors as a mechanism to improve response to ICI |
-
- X. Oncogenes. 1991-93. Lectures on Cytokines and the Role of the Microenvironment in Tumor Progression. 3 hr lecture to ~20 students
 - XI. Cancer Biology. 1992-present. Lectures on tumor specific antigen and hopes for immunotherapy, chemokines and tumor angiogenesis. 3 hour lecture to ~20 students
 - XII. Core Curriculum IGP. 1993-96; 1999-2004. Defense lecture series on cytokines, cytokine receptors and the immune response and/or flex time series on immunology. 2 hour lecture to ~50 students and/or Signal transduction flex time series 3 hr contact time
 - XIII. Advanced Immunology. 1993-2000. Lectures on cytokine or chemokine receptors and signal transduction 4 h our lecture to ~10 students
 - XIV. Organizer: Cancer Biology Research Hour, 2001- 2004.
 - XV. Vascular Biology, 2001-2013. Role of chemokine receptors in angiogenesis.
 - XVI. Cancer Biology, 2001-2005. Role of chemokines in tumorigenesis.
 - XVII. Organizer: Laboratory Management, 2005-. This course was designed to teach MLI students how to effectively manage a laboratory at VUMC.
 - XVIII. Lecture to Undergraduate Research Program and BRIDGES students. Chemokine receptors mediate metastasis. 2007
 - XIX. Melanoma Research Conference for Oncology Fellows: Fall, 2007
 - XX. Department of Cancer Biology Research Conference, Spring, 2011
 - XXI. Breast Cancer SPORE Research Seminar Series, Spring 2011
 - XXII. Cancer Biology Mechanisms of Motility, Fall 2012, 2013
 - XXIII. Department of Medicine, Tortoise and Hare Seminar, 2013
 - XXIV. Epidemiology Postdoctoral Program: Questions in Cancer Biology, 2013
 - XXV. Systems Biology: Cancer Signal Transduction Networks, 2014
 - XXVI. Chemokine Modulation of the Tumor Microenvironment: Effects on Angiogenesis, 2014
 - XXVII. Vascular Biology: How anticancer therapies target tumor angiogenesis, 2015
 - XXVIII. Vascular Diseases Lecture series: Methodologies for investigating angiogenesis, 2015
 - XXIX. CANB342. The interface between cancer and the immune system, 2018-2023

XXX. IGP. Signal Transduction Module 2021, 2022

XXXI. CANB Grant Writing Course, Summer, 2023, 2024

STUDENTS/FELLOWS

ADVISED:

Medical Students:

Jim Mixon, M.D. Effects of pH on 3H-thymidine incorporation in the Hs294T human melanoma cell line. Spring, 1983. Current status: Private Practice

Robert Siegel, M.D. Transforming growth factors in fetal calf serum. Fall, 1982

Rodolpho Bordoni, M.D. Cytokine regulation of MGSA expression in melanoma. 1986-1989, Emory University

Anwell Chang, M.D. Variant CXC chemokine receptors in melanoma. Spring & Summer 1995: Current status: Dermatology residency Case Western

Ashley Long, M.D. Clinical traits of melanoma patients responding to AIK, NF-kB or BRAF inhibitors. Dermatology Faculty, UCSD and VA Medical Center Department of Dermatology

Jessica Smith. AURKA and MDM2 inhibitors for treatment of melanoma tumors, Meharry Medical College

Sesay Williams. Role of IL-4 in the Pro-tumor response to IKK β inhibitor therapy in melanoma. Meharry Medical College

Mallory Holmes. The regulation of the senescence activated secretory program in oncogene and therapy induced senescence. Meharry Medical College

Kiran Malikayil. Effects of AURKA inhibitors combined with MDM2 inhibition on DNA damage. 2015 Meharry Medical College

Kevin Black. PI3Kinase inhibitors combined with Immune therapy for treatment of TNBC. Meharry Medical College

Lauren Slesur: Treatment of malignant melanoma with CDK4/6 and Mdm2 antagonist, VUMC

Kelsie Remenschneider: Treatment of malignant melanoma with AURKA inhibitors and MDM2 antagonist, Residency, MD Anderson

Post-Doctoral Fellows:

H. Greg Thomas, Ph.D. Purification of melanoma growth stimulatory activity by immunoaffinity chromatography and reverse-phase HPLC. 1984-1989. Current role: Vice President for Research, Kiel Laboratories, Gainesville, GA

Jin Hee Han, Ph.D. Characterization of Alternate Forms of MGSA and Characterization of the MGSA Receptor. 1987-1989. Current Position, Professor at Seoul National University, Korea.

Sharon Horton, Ph.D. Characterization of MGSA signals transduction pathways. 1989-90. Head of Forensic Science, State of Tennessee

Rebecca L. Shattuck, Ph.D. Regulation of expression of four genes for MGSA/GRO. 1990-1993. Current position Staff Scientist, Vanderbilt University

Susan Mueller, Ph.D. Expression of cloning of the MGSA receptor, 1991-1995. Current position: Senior Scientist, Hemosol, Inc. Canada

Andrew Farmer, Ph.D. Characterization of novel transcription factor associated with MGSA/GRO gene regulation, 1994-1995. Current position, BD Biosciences, Clontech

Wei Yang, Ph.D., M.D. Domain specificity of chemokine receptors. 1995-1999. M.D. Medical Pathologist, Allen Memorial Hospital, Waterloo, Iowa

C.S. Nirodi, Ph.D. Transcriptional regulation of MGSA genes through phosphorylation of enhancer binding proteins. 1995-2000. Current position: Assistant Professor, tenure track, Southwestern University School of Medicine, Dallas, TX

Tong Tang, Ph.D. Cloning/expression of the mouse DARC receptor, and 1995-1996. Current Position, Scientist, VA Research Service, San Diego, CA

Glendora Carter-Spencer. Chemokine activation of tyrosine kinase signal transduction pathways. 1996-August 1998. Current Position, Professor at Jarvis Christian College, TX

Matt Devalaraja, Ph.D. NF- κ B/I- κ B regulation of chemokine gene transcription. 1997-1999. Current position: Co-Founder and Executive VP of Corvidia Therapeutics and Director of Emerging Innovations at AstraZeneca.

Ding-Zhi Wang, Ph.D. Regulation of gene expression by MGSA/GRO genes. 1997-2000. Current position, Research Professor, Department of Medicine, Medical University of South Carolina, Charleston.

Xue-Jie Wang, Ph.D. Transgenic models for testing the role of CXCR2 in wound healing. 1998-1999. Current position, CEO at Zenomics, RTP, NC

Cunxi Li, MD, PhD. Development of mutant RAS/CDK4/6 null melanocyte cell lines. 1998-2000. Current position. Director, Professor of Jiaen Genetics Laboratories, Jiaen Hospital, Beijing China.

Radika Devalaraja, Ph.D. The role of CXCR2 in wound healing, 1998-1999. Life Sciences Consultant, and Study Director, Toxikon Corporation, Bedford, MA

Guo-Huang Fan, Ph.D. Mechanisms for CXCR2 internalization and desensitization, 1999-2001. Research Instructor, 2001-2002, Research Assistant Professor, 2002-2004. Current position, Associate Dean, Nanchang University and Shanghai Jiao Tong University School of Medicine, Shanghai, China

Punita Dhawan, Ph.D. Upstream activators of IKK in melanoma cells, 1999-2003. Current position, Professor in Biochemistry, University of Nebraska School of Medicine

Yang, Jinming, Ph.D. Is there a general deregulation of IKK in melanoma tumors? 1999 2001; 2002-2004. Current position, Staff Scientist, Department of Pharmacology, VU

Jiqing Sai, Ph.D. The role of rho, rac, cdc42 in chemotaxis mediated through CXCR2. 2000-2005. Research Assistant Professor in Cancer Biology 2006-2016. Current Position: Senior Staff Scientist, Department of Biochemistry, VU

Yukiko Ueda, Ph.D. Characterization of the role of PARP and CDP in transcriptional regulation of CXCL1. (2002-2006). Current position: retired

Ying-jun Su, M.D., Ph.D. The role of NIK and NF- κ B in melanoma tumorigenesis 2003-2007. Current position Assistant Professor of Surgery—4th Medical Military University, Shaanxi, PRC.

Evemie Schutyser, Ph.D. Mechanisms of CXCR3 signal transduction in angiogenesis, 2003-2005. Current position, Medical Manager Specialty Care Benelux At Sobi-Swedish Orphan Biovitrum, Belgium

Paige Baugher, Ph.D. 2005-2008. Chemokine receptor signaling as related to receptor trafficking Current Position: Assoc Prof of Biology with Tenure at Pacifica University, Portland, OR

Tammy Sobolik-Delmaire, Ph.D. 2007-present. Inflammation and Cancer: the role of chemokines. Current Position: Medical Science Liaison with TerSera Therapeutics

Ryan Splittgerber, Ph.D. 2008 to 2010. AIK intersection with IKK in melanoma. Associate Professor, Vanderbilt University—Education Track

Sean Carmody, Ph.D., 2010-2012 The role of VASP in Leukocyte Infiltration and Cell Metastasis. Data Scientist, St Thomas Hospital.

Anna Vilgelm, MD/PhD. 2011-2016. The role of amplification of aurora kinases in melanoma growth and mechanisms of resistance to aurora kinase inhibitors. Assistant Professor (tenure track), Ohio State University

Yan Liu, PhD. 2010-2013. Mechanisms of action of Aurora Kinase Inhibitors and IKK-beta inhibitors. Staff Scientist, UT Southwestern

Oriana E. Hawkins, PhD. 2010-13. Effects of chemotherapeutics on leukocytes in the tumor microenvironment. Director of Assay Development at ENT vantage DX, Texas

Jeff Pawilikowski, PhD, 2014-2015. Oncogene events during early progression of melanoma. Medical Science Liaison, Jassen Pharmaceuticals

Nicole Lavender (Krupp), PhD. 2014-2016. New approaches for therapeutic modulation of the tumor microenvironment in triple negative breast cancer. Current Position, Medical Science Liaison, Boehringer Ingelheim

Stacey Mont, PhD. 2017-2018. Developing new therapies for TNBC using PI3K inhibitors and immune therapy. Merck Pharmaceuticals

Chi Yan, PhD: 2018-2020. Designing better therapeutic options for NRAS mutant melanoma Research Assistant Professor, 2020-present, Richmond lab.

Carly Bess Williams Scalise, PhD. 2019-2020. Combining PI3K Pathway Inhibitors with Immune Checkpoint Blockade. Scientist, Translational Medicine, Natera, Birmingham, AL

Caroline Nebhan, MD/PhD: 2019-2022. Improving response to ICI inhibitors in melanoma. Oncology Clinical Practice Intermountain Oncology, Utah

Lindsey Seldin: 2020-2022 The role of dermal fibroblasts in skin cancer. Assistant Professor at Emory University

Weifeng Luo, PhD. 2021- Mechanisms of action of ipatasertib in triple negative breast cancer. Staff Scientist, Vanderbilt University

Kensley Bergdorf, PhD. 2022- Using patient melanoma organoid/immune cell co-cultures to predict responsiveness of targeted therapy combined with immune checkpoint inhibitor.

Graduate Students:

Eddy Balentien, Molecular Biology of Melanoma Growth Stimulatory Activity (MGSA): Molecular Cloning, Eukaryotic Expression, Characterization of Signal Transduction Mechanism, and Evaluation of Tumorigenic Potential, 1985-1990. Current position: Associate Director of the Immunology Clinical Labs, Curacao, Netherlands Antilles.

*Lauren Wood, Transcriptional control of the MGSA genes, 1990-1995. Current position, Senior Principal Scientist, Pfizer-San Diego, CA

* *Recipient of a University Scholars Award for Topping up Tuition for Graduate School*

*James Owen, Transforming potential of MGSA isoforms, 1993-1996. Current position, Manager, Business Development AVEO Pharmaceuticals

* *Recipient of an individual NSRA for studies on chemokines in liver disease*

Jing Luan, M.S., M.D. Differential regulation of MGSA genes and receptors in human skin cancers, 1995-1999. Current position, Hospitalist, Burlington Medical Association, Boston, Mass.

Jessie Hart, The role of chemokines and their receptors in vascular biology during the aging process. 2000-2001. Current Position, US Armed Forces

Kathy Amiri, Ph.D. The role of CBP in the transcriptional regulation of chemokines. 2001-2005; Current position, Vice President, Head of Global Medical Affairs Strategy, Solid Tumors. Genmab, NY

Nicole Fowler Neel, Ph.D. Characterization of the CXCR2 and CXCR4 chemo-synapse. 2002-2008
Current Position: Science Writer for INC. Chapel Hill, NC.

Yee Mon Thu. The role of NIK in melanoma tumor growth and transformation. 2006-2011. Current position, Assistant Professor Colby College

Katie Hutchinson (co-mentor) 2014 Genetic changes in malignant melanoma affecting drug response. 2009-2014. Current position: Scientist, Genentech, South San Francisco, CA

Kennady Bulloch Mechanisms of resistance to AKT inhibition in Triple Negative Breast Cancer. 2021-2024. Postdoctoral Research, Moffit Cancer Center with Patrick Hua.

Undergraduate Students:

Aimee Cunningham. The use of RMCE to follow transcriptional regulation of CXCL1. Masters of Public Health Program, Emory University followed by Medical School.

Andy B. Collier: Mouse models of melanoma—Vanderbilt undergraduate student. Currently, M.D.

Vinh Lam: Signal transduction through chemokine receptors. Currently, M.D.

Beth Reed. The role of mutation of CXCR2 in cutaneous wound healing. Physicians Assistant, Nashville, TN

Kevin Vo Pharm D. Chemokine receptor animal models for tumor angiogenesis, Director of Clinical Operations, Medical Oncology, Alliance Oncol

Deepa Joshi. Gene expression profile of CXCR4- Δ CTD MCF7 cells as compared to CXCR4 WT expressing cells. Vanderbilt Medical School--now Pediatrician at Johns Hopkins Bloomberg School of Public Health

Peter DelNero. Development of devices to monitor paracrine and autocrine interactions in tumors. Current Position: Graduate School, Cornell University followed by postdoc at NCI

Sara Short. Characterization of the role of CXCR4 in breast cancer metastasis. Current Position, Research Assistant Professor, University of Iowa.

Zar Min. The role of NIK in melanoma tumor growth. (MTSU student).

Kate Hockmeyer. Bioreactors for co-culture metastasis studies. Current position: MSTP student NYU Medical School

Tyesha Martin. IL-4 receptor antagonist for treatment of melanoma in combination with IKK β inhibitors (TSU student), Dental School

Carla Gibbs. TRAIL activation of DR5 enhances the therapeutic response to MLN8237 in melanoma. (TSU student summer research). Graduate Student, Meharry Medical School

Karina Lopez. The role of phospholipase A2 in response to a chemokine gradient. TSU student

Maria Boyer. Effects of senescence on chemokine gene expression. Fisk University student. –Completed her law degree from Santa Clara University School of Law, 2020

Matthew Rodgers. Construction and utilization of microbioreactors for study of the human tumor microenvironment. Currently graduate student at Vanderbilt University in Chemical Engineering

Logan Northcutt. CCL2 mediation of neutrophil killing. Morehouse University. Now Vanderbilt IGP graduate student in Cancer Biology and Bioengineering

Kennady Bullock. Developing therapies for NRAS mutant melanoma. Vanderbilt undergraduate student, Fall, 2017 through May, 2018. Currently, a graduate student in Pharmacology, Richmond lab

Katelyn Atkinson. Rigosertib as an inhibitor of melanoma tumor growth, TSU undergraduate student, summer, 2018

Toran Kirkland. Ipatasertib as an inhibitor for TNBC growth. TSU undergraduate student. Current Position: Pharm D student at Mercer University, Atlanta, GA

Zhizhu Zhang. CXCR2 inhibitors in combination with immune checkpoint inhibitors for cancer therapy. Vanderbilt undergraduate. 2019-present, Harvard School of Public Health and Epidemiology

Tiara Oldfield, Rigosertib as a therapeutic for malignant melanoma in combination with anti-PD1. Vanderbilt undergraduate. 2020-2021

Judy Min: The PI3K pathway inhibition in breast cancers, Research position, Harvard Medical School/ Dana Farber Cancer Center

Maggie Zhou: 2022-2024. Effect of inhibition of CD40 expression on response to rigosertib in melanoma cells. Junior and Senior Year undergraduate student, Vanderbilt University. Honors thesis Research.

Oncology Fellow and Clinical Investigators:

Rodolfo Bordoni, M.D. Growth Factor/Cytokine activation of MGSA mRNA, 1987-1989. Current Position: Private Practice, Atlanta, GA.

Anthony Daniels, M.D. New Interventional Approaches for Retinoblastoma and Ocular Melanoma. 2014-present. Assistant Professor of Ophthalmology, VUMC

Caroline Nebhan, M.D/Ph.D. Using targeted therapies to enhance response to immune therapy in melanoma, 2019-2022. Clinical practice, Intermountain Oncology, Utah

Assistant Professors:

Phil Owens, Ph.D. PI3K inhibitors enhance the response to immune therapy in TNBC—Asst Professor, University of Colorado

Shanna Arnold, Ph.D. ALCAM as a marker for tumor progression in bladder cancer—Sara Cannon Healthcare Specialist—Program management

John Wilson, Ph.D. Sting agonists enhance response to immune therapy, Assoc Professor Vanderbilt

Deepak Son, Ph.D. Chemokines as mediators of tumor progression in obesity—now full professor at Meharry Medical College

Amos Sakwe, Ph.D. Tyrosine kinases that combine with EGFR to modulate growth of breast cancer- Associate Professor at Meharry Medical College at this time

Brent Ferrell, M.D. Improving therapeutics for hematopoietic cancers, Asst Professor, VUMC

Richard O’Neil, PhD. Engineered T cells for delivery of anti-cancer therapeutics, Asst Professor, MUSC

Anna E. Vilgelm, MD/PhD. MDM2 antagonists enhance response to AURKA and CDK4/6 inhibitors in malignant melanoma, Assistant Professor, The Ohio State University

Chi Yan, Ph.D. CD40 modulates response of melanoma tumors to rigosertib plus immune checkpoint inhibitors—now Research Assistant Professor, Vanderbilt

PRIMARY RESEARCH

PRESENTATIONS Last 19 Years:

Local:

- 3/01 Cancer Biology Research Hour, VUMC
- 5/01 Vanderbilt Biomedical Research Graduate Student Association Meeting (slide)
- 6/01 Signal Transduction Subgroup of VICC
- 4/03 Rheumatology Conference, Vanderbilt University
- 5/03 Melanoma Conference, Vanderbilt University School of Medicine
- 4/05 Melanoma Conference, VUMC
- 3/06 Inflammation and Cancer, VUMC
- 5/06 Host-Tumor Interactions, VICC Mini Retreat
- 03/07 Department of Microbiology and Immunology

03/07 Meharry Medical College Department of Cancer Biology

10/07 Melanoma Seminar Series

08/07 Summer Science Enrichment Program—VUMC

10/08 VUMC/Meharry U54 Cancer Retreat—Panel Discussion Career Planning

02/09 Women on Track—Professional Development

01/09 VUMC/Meharry U54 **Cancer** Retreat—Panel Discussion Career Planning

05/09 VUMC Workshop, Preparing Research Team Leaders—Panel Discussion member and small group leader.

07/10 Summer Science Workshop Keynote Speaker

04/11 Department of Cancer Biology Research Forum

05/11 Breast Cancer SPORE Research Program

01/14 Host Tumor Interactions Program

01/14 Melanoma Program

11/14 Vascular Biology Program

12/14 Department of Pathology, Microbiology and Immunology Seminar Program

06/15 Vascular Diseases Seminar Program

01/16 Vanderbilt Ingram Cancer Center Executive Committee

04/16 Tumor Immunology Group

03/17 VICC Update on NCI PDX Supplement

05/17 Tumor Immunology Working Group

10/17 Program in Cancer Biology Science Hour

09/18 VICC Tumor Microenvironment and Immunology Program

03/18 Department of Pharmacology Seminar Series

04/19 Department of Pharmacology Faculty Feed

10/19 Cancer Research for Medical Student Immersion Studies

02/20 VICC CCSG Site Visit Renewal

07/20 Meharry Medical School Research Presentation

07/21 Forum on Melanoma and Therapeutic Advances—Organizer and Discussion Leader

10/21 Program in Cancer Biology Science Hour Presentation.

03/22 T32/K12 Vanderbilt Oncology Training Program Retreat

05/23 VICC Breast SPORE

National:

04/01 Keystone Conference on Signal Transduction: "Chemokine Receptor Signal Transduction" also Program Organizer Committee

01/02 New York University, "Mechanisms of transcriptional deregulation of chemokines in tumorigenesis".

04/02 University of Michigan, "Signals of biological importance mediated through CXCR2"

03/03 Invited participant in the State of Georgia Cancer Research Initiative, Georgia Tech, Atlanta, GA

10/03 Invited Plenary Session Speaker, Society for Leukocyte Biology, Philadelphia, PA. Co-Chair for Chemokines Symposium.

04/03 MD Anderson, "Dis-regulation of NF-kB in melanoma tumor progression"

04/03 AACR meeting in Toronto, poster presentation by student Kathy Amiri

01/04 Visiting Scientist, Bristol Myer Squibb

04/04 Visiting Scientist, University of Tennessee Department of Microbiology. Seminar "The ins and outs of chemokine receptor trafficking".

05/04 Visiting Scientist, University of Texas Medical Branch at Galveston.

05/04 Keynote Speaker, Wound Healing Society, "Chemokine Receptors Modulate Wound Healing and Angiogenesis"

06/04 Plenary Speaker, Carcinogenesis and Cancer Prevention- Implication of Pigment Cell Biology for Understanding Human Diseases, International Pigment Cell Congress, Newport Beach, CA

08/04 Visiting Scientist, University of Texas Medical Branch "Rationale for Inhibiting NF-kB in Melanoma"

02/05 Gordon Research Conference on Chemotaxis and Motility, Ventura California

04/05 Loyola University, Department of Immunology, Chicago "Targeting NF-kB in Melanoma"

05/05 Eli Lilly, Indianapolis, IN "Is NF-kB a Target for Cancer Therapy"

10/05 Visiting Scientist, University of Utah "Targeting the NF-kB Pathway in Melanoma"

12/05 Speaker, Vanderbilt Alumni Meeting Houston TX "Genius at Work"

01/06 Session Chair/Discussion Leader, Keystone Conference on Chemotactic Cytokines, Snowbird, Utah

01/06 Invited Plenary Session Speaker, Keystone Conference on Advances in the Understanding and Treatment of Melanoma, Santa Fe, NM

05/06 Keynote speaker, Melanoma Symposium, Penn State Medical Center, Hershey PA "Targeting NF-kB in Melanoma."

8/06 Speaker, Grand Rounds in Pathology, Oklahoma Health Science Center, Oklahoma City, OK "Targeting NF-kB in Melanoma"

09/06 The role of NIK in melanoma transformation, Eli Lilly, Indianapolis, IN

9/06 Speaker, ISOBM Symposium, Pasadena CA "Inhibition of IKK blocks melanoma tumor growth"

01/07 Speaker, Gordon Research Conference on Gradient Sensing, Ventura, California

04/07 Speaker, AACR. Chemokine receptors in inflammation, angiogenesis and wound repair. Los Angeles, CA.

05/07 Visiting Scientist, North Carolina Central University: Chemokine Receptor Trafficking

01/08 University of Kansas, Visiting Scientist

01/08 Keystone Conference on Chemotactic Cytokines, Keystone CO—Workshop leader

04/08 Keystone Conference on Inflammation and Cancer, Snowbird, UT—plenary speaker and Session Discussion Leader

05/08 University of Louisville, Visiting Scientist, Brown Cancer Center

05/08 University of Nebraska, Visiting Scientist

08/08 Louisiana State University at New Orleans, Visiting Scientist

11/08 Brown University, Department of Biology, Visiting Scientist

04/09 AACR National Meeting Speaker. Mentoring Session, Denver, CO

05/09 Gordon Research Conference on Gradient Sensing— UTMB, Galveston Cancer Center, VisitingScientist Galveston, TX
Plenary speaker

11/09 Cleveland Clinic, Visiting Scientist

04/10 Keynote Speaker at GREAT Meeting at the University of Oklahoma

05/10 Visiting Scientist, U of Kentucky, Lexington, Cancer Center

05/10 NIH TEMEN meeting on Gradient and Flow of Soluble Factors in the Tumor Microenvironment Workshop, Bethesda, MD

06/10 Visiting Scientist, Albert Einstein School of Medicine, New York, NY

01/11 Visiting Scientist, University of Iowa, Department of Pharmacology, Iowa City IO

05/11 Visiting Scientist, NCI Laboratory of Cancer Biology and Genetics, Bethesda, MD

07/11 University of Kentucky Cancer Center, Lexington, KY

09/11 Translational Research Conference, NIH

10/11 AACR Breast Cancer Symposium, San Francisco, CA

11/11 International Melanoma Congress, Tampa Florida

11/11 TMEN AACR meeting, Orlando, FL

03/12 Cell signaling and cytoskeleton in directed cell migration: Imaging and quantitative approaches” Conference, Vanderbilt University, Nashville, TN

4/12 AACR Workshop for Postdocs and Graduate Student Associate Members

1/12 Women in Cancer Research Leadership Workshop, “Managing for results in today’s challenging climate” AACR national meeting workshop, Chicago IL.

10/12 Society of Leukocyte Biology Annual Meeting, “Chemokine Entrainment of the Leukocytes in the Tumor Microenvironment and Premetastatic Niche”, Maui, Hawaii

10/13 Society of Leukocyte Biology Annual Meeting, “Creating a Mentoring Network”, Newport Beach, RI

12/13 “Inflammation Drives Cancer and Therapeutic Response to Chemotherapy are modified by Tumor associated leukocytes.” Montana State University, Bozeman, MT

07/14 Gordon Research Conference on “Chemokines and Chemokine Receptors”; Session Chair.

10/14 Society for Leukocyte Biology, Session Chair, Salt Lake City, Utah

11/14 “Chemokines modulate tumor metastasis.” University of Southern Alabama, Mobile, AL

03/15 “Novel therapeutic approaches for melanoma and breast cancer therapy.” Markey Cancer Center, Lexington KY.

09/15 Society of Leukocyte Biology, Session Chair, Raleigh Durham, NC

11/15 AACR Conference “Advances in Malignant Melanoma,” Philadelphia, PA

01/16 “Targeted therapies modulate anti-cancer immunity.” Breast Cancer Program, University of Iowa, Iowa City, Iowa

03/16 “Cancer therapeutics that induce senescence can enhance recruitment of effector T cells to tumors”. Distinguished speaker Tumor Immunology Program, MD Anderson, Houston TX

04/16 2016 AACR Annual Meeting. “19th Annual Grant Writing Workshop” Mentor. New Orleans, LA.

05/16 Society for Leukocyte Biology, Session Chair, Crystal City, VA

09/16 “Targeted therapies modulate anti-cancer immunity in melanoma and breast cancer.” Department of Biochemistry and Molecular Biology, U of Nebraska, Omaha, Nebraska.

10/16 University of Nebraska Medical Center, Department of Biochemistry and molecular Biology. “Targeted Therapies that enhance response to Immunotherapy” Guest speaker. Omaha, NE

- 11/16 Society for Melanoma Research Congress, “13th International Congress of the Society for Melanoma Research.” PRCRP MOSC Panel and Peer review plus conference attendee.
- 04/17 American Association for Cancer Research Annual Meeting. Round table discussion leader and Grant Review Panel Speaker
- 05/17 Cancer Immunotherapy: Advances and Challenges, Third National Veterans Health Affairs Research Conference. Keynote Speaker, Nashville, TN
- 09/17 TRIST Symposium “New combinations of senescence inducing therapy combined with immune therapy for melanoma patients.” Northwestern University School of Medicine. Chicago IL. Guest Speaker
- 03/18 U Chicago Committee on Cancer Biology Seminar, “Senescence Inducing Targeted Therapies that Enhance Response to Immune checkpoint Inhibitors” Speaker. University of Chicago, Chicago, IL
- 04/18 AACR Annual Meeting Chicago Roundtable Discussion Leader
- 06/18 Gordon Research Conference, “2018 Chemotactic Cytokines” in Newry Maine. Presented poster
- 07/18 Gordon Research Conference on Chemotactic Cytokines, “CXCR4 plays a major role in Tumor Growth and Metastasis and antagonizing CXCR4 reduces NK anti-tumor cell activity.” Sunday River, Maine
- 10/18 Society for Leukocyte Biology (SLB), Ambassador for the JLB in Boston at the ICIS meeting. Boston, MA
- 10/18 Society for Leukocyte Biology (SLB) 2018 JLB Senior Editorial Board meeting. Attended conference “Myeloid Cells: Development, Environment and Inflammation” Phoenix, AZ
- 01/19 NIH “Translational and Clinical Sciences Provocative Questions Workshop” Rockland, MD
- 03/19 University of Texas Health Science Center, Guest speaker. San Antonio TX
- 03/19 “How to Improve Response to Immune Checkpoint Inhibitor Therapy”, Medical University of South Carolina, Visiting Scientist.
- 06/19 Southeastern Immunology Symposium, “Immunologic Diseases and Basic Immunology” Atlanta GA
- 06/19 University of Colorado Denver, 2019 King Endowed Lectureship Symposium, Keynote Speaker. Denver, CO
- 04/21 Sylvester Cancer Center Symposium Speaker, Miami, FL—
- 05/20 Tisch Cancer Center, Mt Sinai School of Medicine, NYC—postponed due to COVID
- 06/20 CIRP ANNUAL MEETING U54/NCI, Rockland MD--Zoom
- 08/20 Midwest Tumor Microenvironment Symposium, Kansas City, Kansas—postponed due to COVID
- 08/20 Radiation, Senescence, and Cancer, NCI workshop, Shady Grove, MD—Zoom
- 09/21 Pathobiology Graduate Program at Brown University. Keynote Speaker and Program Evaluation

- 5/22 Susan Lester Lecture at the Markey Cancer Center Research Day
- 5/22 Speaker at the University of Kansas Cancer Biology Program and visiting scientist

International:

- 11/00 International Cytokine Society. "Modulation of chemokine signaling involves multiple receptor-associated proteins. Maui, Hawaii: also Chair for Plenary session on Chemokines
- 05/02 Chemokine Meeting in Madrid, Spain—Invited Plenary Speaker
- 07/02 Gordon Research Conference on Chemotactic Cytokines—Invited Plenary speaker
- 10/02 International Cytokine Society. "Chemokine Receptor Trafficking", Torino, Italy
- 9/02 Novartis Foundation Symposium, London UK.—Invited Plenary Speaker
- 01/03 Keystone Symposium on Chemokines and Chemokine Receptors, Beaver Run, Co. Meeting Organizer and Invited Speaker
- 03/03 Invited Plenary Session Speaker, Chemokines in Immunity, 6th European Winter Conference in Immunity, St Sorlin workshop, France (declined)
- 05/03 Invited Plenary Session Speaker, Federation of Clinical Immunology Societies (FOCIS) Paris, France (declined)
- 09/03 Invited Plenary Session Speaker, International Cytokine Society, Dublin, Ireland
- 07/04 Invited Plenary Session Speaker, Canadian Immunology Society, Montreal, Canada
- 09/04 Invited Plenary Session Speaker, Gordon Research Conference on Chemotactic Cytokines, France
- 05/06 Speaker, CNIO Cancer Conference, Inflammation and Cancer, Madrid Spain, "Targeting NF-kB in Melanoma"
- 9/08 Gordon Research Conference on Chemotactic Cytokines, plenary speaker and session Discussion Leader. Aussois, France
- 04/10 AACR Forum Speaker:" Animal Models for preclinical Evaluation of Drugs for Metastatic Disease: Are GEMs the Jewel in the Crown or an Expensive Luxury? Plenary Speaker
- 05/10 Gordon Research Conference on Chemotactic Cytokines and their Receptors, Lucca, Italy, Plenary Speaker
- 09/11 Symposium Speaker, Academia Sinica, Institute of Biomedical Sciences, "International Symposium on Inflammation and Diseases", Taiwan—invited but unable to attend
- 5/12 Gordon Research Conference on Chemotactic Cytokines, Barga Italy. Plenary Session speaker

06/16 Gordon Research Conference for Chemotactic Cytokines and Chemokine Receptors, Spain

08/16 Society for Leukocyte Biology, Verona, Italy, Session Chair and poster presentation.

07/17 Chemokines as modulators of response to immune therapy. Dalhousie University, Halifax Canada.

10/17 Society of Leukocyte Biology Annual Meeting. Vancouver, Canada. Session Chair.

11/19 Society for Leukocyte Biology (SLB) 2019 Annual Meeting, Career Roundtable Event. Boston, MA and Keynote Speaker for Legacy Award

07/21 South African Conference on Immunology (FAIS), Zoom speaker, SLB Sponsored

06/22 Gordon Research Conference on Chemokines, Plenary speaker, Switzerland— and Director of the Power Hour for Women Scientists

08/22 Society for Leukocyte Biology, Session Chair and Speaker, Hawaii

03/23 Round table discussion leader at the Melanoma Research Alliance meeting, Washington DC

03/24 Melanoma Research Alliance Meeting, Invited Participant, Washington, DC

04/24 AACR 2024, San Diego, CA, poster presentation by Kennady Bullock

05/24 Trainee presentation at the American Association of Immunology, Chicago, IL

06/24 Chemotactic Cytokines and Receptors Gordon Research Conference, Portland, MA

03/25 GPCR Gordon Research Conference—Plenary Session Speaker